[go: up one dir, main page]

WO2003066672A1 - Peptides - Google Patents

Peptides Download PDF

Info

Publication number
WO2003066672A1
WO2003066672A1 PCT/JP2003/001333 JP0301333W WO03066672A1 WO 2003066672 A1 WO2003066672 A1 WO 2003066672A1 JP 0301333 W JP0301333 W JP 0301333W WO 03066672 A1 WO03066672 A1 WO 03066672A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
acid sequence
seq
active ingredient
Prior art date
Application number
PCT/JP2003/001333
Other languages
English (en)
French (fr)
Inventor
Kenji Sakamoto
Original Assignee
Nakoshi, Hideo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nakoshi, Hideo filed Critical Nakoshi, Hideo
Priority to AU2003211501A priority Critical patent/AU2003211501A1/en
Priority to JP2003566043A priority patent/JPWO2003066672A1/ja
Publication of WO2003066672A1 publication Critical patent/WO2003066672A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to peptides. More specifically, the present invention relates to a peptide having an insulin production promoting effect, a gastric acid secretion suppressing effect, a growth hormone production promoting effect, a blood pressure lowering effect, a fat accumulation suppressing effect, an allergy suppressing effect, an analgesic effect, and a central nervous system function promoting effect.
  • An object of the present invention is to provide a peptide which is particularly useful as a medicine or food. Disclosure of the invention
  • the inventors of the present invention have conducted intensive studies to solve the above problems, and as a result, have found that a peptide having a specific amino acid sequence has excellent physiological activity and is particularly useful as a medicine or a food. Was completed.
  • the present invention relates to a peptide having the amino acid sequence represented by SEQ ID NO: 1 in the sequence listing, or substitution or deletion of one or more amino acids in the amino acid sequence, or substitution of one or more amino acids in the amino acid sequence.
  • a peptide having an insulin production promoting effect a peptide comprising the peptide as an active ingredient, an insulin production enhancer comprising these peptides, and an insulin production enhancer comprising the peptide as an active ingredient.
  • the present invention relates to a peptide having an amino acid sequence represented by SEQ ID NO: 2 in the sequence listing, or one or more amino acids in the amino acid sequence are substituted or deleted, or one or more amino acids are substituted in the amino acid sequence.
  • the present invention relates to a peptide having an amino acid sequence represented by SEQ ID NO: 3 in the sequence listing, or one or more amino acids in the amino acid sequence are substituted or deleted, or one or more amino acids are substituted in the amino acid sequence.
  • a medicament or a food such as a growth hormone production promoter containing the above-mentioned peptide as an active ingredient.
  • the present invention relates to a peptide having the amino acid sequence represented by SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, or 12 in the sequence listing, or 1 Or a peptide having an amino acid sequence in which a plurality of amino acids are substituted or deleted, or in which one or more amino acids are inserted or added to the amino acid sequence, and which has a blood pressure lowering effect.
  • Pharmaceuticals or foods such as a peptide containing the peptide as an active ingredient, a blood pressure lowering agent comprising these peptides, and a blood pressure lowering agent containing the peptide as an active ingredient.
  • the present invention relates to a peptide having the amino acid sequence represented by SEQ ID NO: 13, 14, 15, 15, 16, 17 or 18 in the sequence listing, A peptide having an amino acid sequence in which one or more amino acids in the amino acid sequence have been substituted or deleted, or an amino acid sequence in which one or more amino acids have been inserted or added to the amino acid sequence, and Pharmaceuticals or foods such as peptides having an antibacterial effect, peptides containing the peptides as active ingredients, fat accumulation inhibitors composed of these peptides, and fat accumulation inhibitors containing the peptides as active ingredients.
  • the present invention provides a peptide having an amino acid sequence represented by SEQ ID NO: 19 in the sequence listing, or a substitution or deletion of one or more amino acids in the amino acid sequence, or A peptide having an amino acid sequence in which one or more amino acids are inserted or added, wherein the peptide has an allergy-suppressing effect; Peptide to the peptide as an active ingredient, a pharmaceutical or a food such as those โ‡ les-saving one inhibitor consisting of peptides, and allele formic one inhibitor comprising the base peptide as an active ingredient.
  • the present invention relates to a peptide having an amino acid sequence represented by SEQ ID NO: 20, 21, or 22, or one or more amino acids in the amino acid sequence are substituted or deleted, or the amino acid A peptide having an amino acid sequence in which one or more amino acids are inserted or added to the sequence, the peptide having a blood pressure lowering effect, a peptide containing the peptide as an active ingredient, a blood pressure lowering agent comprising these peptides And a medicine or food, such as a hypotensive agent, containing the above-mentioned peptide as an active ingredient.
  • the present invention provides a peptide having the amino acid sequence represented by SEQ ID NO: 23 or 24, or substitution or deletion of one or more amino acids in the amino acid sequence, or Or a peptide having an amino acid sequence in which a plurality of amino acids are inserted or added, the peptide having an analgesic effect, a peptide containing the peptide as an active ingredient, an analgesic comprising the peptide, and the aforementioned It is a drug or food such as an analgesic containing a peptide as an active ingredient.
  • the present invention relates to a peptide having the amino acid sequence represented by SEQ ID NO: 25, 26, 27, 28, 29, 30, 31 or 32, or 1 Or a peptide having an amino acid sequence in which a plurality of amino acids are substituted or deleted, or in which one or more amino acids are inserted or added to the amino acid sequence, and which has a central nervous system function promoting effect.
  • Pharmaceuticals or foods such as a peptide, a peptide containing the peptide as an active ingredient, a central nervous system function promoter comprising the peptide, and a central nervous system function promoter containing the peptide as an active ingredient.
  • the peptide according to the first invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 1 in the sequence listing. Since the peptide has a function of promoting insulin production, it is useful as an insulin production promoter and is applied to medicines, foods, and the like. For example, the peptide according to the first invention is blended as an active ingredient, and is applied to medicines, foods, etc., such as insulin production promoters. Among these, the insulin production promoter as a medicament can be used for the treatment and prevention of diabetes, and its application as a therapeutic agent for diabetes is also included in the category of the insulin production promoter of the present invention.
  • a peptide having a physiological activity has a small number of amino acid sequences substituted or deleted in the amino acid sequence, or a small number of amino acid sequences inserted or added to the amino acid sequence. It is well known to those skilled in the art that the physiological activity may be maintained. Therefore, one or more amino acids in the amino acid sequence shown in SEQ ID NO: 1 are substituted or deleted, or a peptide having an amino acid sequence in which one or more amino acids are inserted or added to the amino acid sequence. Further, peptides having an insulin production promoting effect are also included in the scope of the peptides according to the first invention of the present invention.
  • the amino acid sequence of such a peptide is shown in SEQ ID NO: It is preferred that it has 70% or more, more preferably 90% or more homology with the amino acid sequence represented by 1.
  • the insulin production promoting agent as the medicament according to the first invention is administered orally administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration.
  • a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration.
  • the dosage is determined appropriately based on the condition of the patient, the molecular weight of the active ingredient, and the like.
  • the body weight is preferably 1 kg and the daily dose is preferably about 0.1 mg to 0.1 mg.
  • the weight is preferably about 1 kg and about 0.1 mg to 1 Omg per day.
  • the insulin production promoter comprising the peptide according to the first invention can be appropriately formulated by a conventional method.
  • the insulin production promoter is dissolved in physiological saline in a concentration range of 30 mg / l to 300 mg Z1. Can be used.
  • oral administration it can be added to beverages to form a so-called drink.
  • the peptide according to the second invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 2 in the sequence listing. Since the peptide has a function of suppressing gastric acid secretion, it is useful as a gastric acid secretion inhibitor and is applied to medicines, foods, and the like.
  • the peptide according to the second invention is blended as an active ingredient and applied to medicines, foods and the like such as gastric acid secretion inhibitors.
  • the gastric acid secretion inhibitor as a medicament can be used for treatment and prevention of gastric ulcer and duodenal ulcer, and the application as a gastrointestinal drug is also included in the scope of the gastric acid secretion inhibitor of the present invention.
  • one or more amino acids in the amino acid sequence shown in SEQ ID NO: 2 are substituted or deleted, or one or more amino acids are inserted in the amino acid sequence, or Peptides having an added amino acid sequence and having a gastric acid secretion inhibitory effect are also included in the scope of the peptides according to the second invention of the present invention. It is preferable that the amino acid sequence of such a peptide has 70% or more, more preferably 90% or more homology with the amino acid sequence represented by SEQ ID NO: 2.
  • the gastric acid secretion inhibitor as a medicament according to the second invention is preferably administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration, or orally.
  • the dosage is determined appropriately based on the condition of the patient, the molecular weight of the active ingredient, and the like.
  • the body weight is preferably 1 kg and the daily dose is preferably about 0.01 mg to 1 mg.
  • the body weight is preferably 1 kg, and about 0.1 to 10 mg per day is preferable.
  • the gastric acid secretion inhibitor comprising the peptide according to the second invention can be appropriately formulated by a conventional method, for example, a concentration of 30 mgZl to 300 mg / l in physiological saline. It is possible to use those dissolved within the range.
  • a so-called drink can be added to a beverage.
  • the peptide according to the third invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 3 in the sequence listing. Since the peptide has a function of promoting the production of growth hormone, it is useful as a growth hormone production promoter and is applied to medicines, foods, and the like.
  • the above-mentioned peptide according to the third aspect of the present invention is blended as an active ingredient and applied to pharmaceuticals such as growth hormone production promoters, foods and the like.
  • the growth hormone production promoter as a medicine can be used for treating dwarfism.
  • amino acids in the amino acid sequence shown in SEQ ID NO: 3 are substituted or deleted, or one or more amino acids are inserted into the amino acid sequence or Peptides having an added amino acid sequence and having a growth hormone production promoting effect are also included in the scope of the peptide according to the third invention of the present invention. It is preferable that the amino acid sequence of such a peptide has 70% or more, more preferably 90% or more homology with the amino acid sequence represented by SEQ ID NO: 3.
  • the growth hormone production promoter as a medicament according to the third invention is preferably administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration, or orally. Also, the dose depends on the patient It is appropriately determined based on the condition of the individual, the molecular weight of the active ingredient, etc., but in general, the body weight is preferably 1 kg for parenteral administration and about 0.01 to 1 mg per day, and the weight for oral administration. 1 kg, about 0.1 mg to 10 mg per day is preferable. Further, the growth hormone production promoter comprising the peptide according to the third invention can be appropriately formulated by a conventional method, for example, in a concentration range of 30 mgZl to 300 mgZ1 in physiological saline. A dissolved one can be used. In the case of oral administration, a so-called drink can be added to a beverage.
  • a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration, or orally.
  • the peptide according to the fourth invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, or 12 in the sequence listing. Since the peptide has a function of lowering blood pressure, it is useful as a blood pressure lowering agent, and is applied to medicines, foods, and the like.
  • the above-mentioned peptide according to the fourth aspect of the present invention is blended as an active ingredient, and is applied to medicines, foods and the like such as antihypertensive agents.
  • the antihypertensive agent as a medicament can be used for treatment and prevention of hypertension, and its application as an antihypertensive agent is also included in the category of the antihypertensive agent of the present invention.
  • amino acids in the amino acid sequence shown in SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, or 12 are substituted.
  • a peptide having an amino acid sequence in which the amino acid sequence is deleted or deleted, or one or more amino acids are inserted or added in the amino acid sequence, and which has a blood pressure lowering effect is also a fourth invention of the present invention.
  • the amino acid sequence of such a peptide has at least 70%, more preferably at least 90%, the amino acid sequence represented by SEQ ID NOs: 4, 5, 6, 7, 8, 9, 10, 11, or 12. Preferably, they have homology.
  • the antihypertensive agent as a medicament according to the fourth aspect of the present invention is preferably administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, rectal administration or oral administration. Dosage may vary depending on patient condition and It is determined as appropriate based on the molecular weight of the active ingredient, etc., but in general, parenteral administration is preferably lkg in body weight, and 0.0 lmg per day or more: about Lmg is preferable. About 0.1 to 10 mg per day is preferred.
  • the antihypertensive agent comprising the peptide according to the fourth aspect of the present invention can be appropriately formulated by a conventional method.
  • a solution obtained by dissolving in a physiological saline solution in a concentration range of 30 mg / l to 300 OmgZl is used.
  • a so-called drink can be added to a beverage.
  • the peptide according to the fifth invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 13, 14, 15, 16, 17 or 18 in the sequence listing. Since the peptide has a function of suppressing fat accumulation (fat accumulation suppressing effect), it is useful as a fat accumulation inhibitor, and is applied to medicines, foods, and the like.
  • the peptide according to the fifth aspect of the present invention is blended as an active ingredient, and is applied to medicines, foods and the like such as fat accumulation inhibitors.
  • the fat accumulation inhibitor as a medicament can be used for the treatment and prevention of hypolipidemia
  • the fat accumulation inhibitor of the present invention can be used as an agent for hyperlipidemia, a therapeutic agent for obesity, and an agent for preventing obesity. It is included in the category of accumulation inhibitors.
  • a peptide having a physiological activity has a small number of amino acid sequences substituted or deleted in the amino acid sequence, or a small number of amino acid sequences inserted or added to the amino acid sequence. It is well known to those skilled in the art that the physiological activity may be maintained. Therefore, one or more amino acids in the amino acid sequence shown in SEQ ID NO: 13, 14, 15, 15, 16, 17 or 18 are substituted or deleted, or one or more amino acids are added to the amino acid sequence.
  • Peptides having an amino acid sequence in which the amino acid is inserted or added and having an effect of suppressing fat accumulation are also included in the scope of the peptide according to the fifth invention of the present invention.
  • the amino acid sequence of such a peptide is at least 70%, more preferably at least 90%, the amino acid sequence represented by SEQ ID NOS: 13, 14, 15, 16, 17 or 18. It is preferable to have the above homology.
  • the fat accumulation inhibitor as a medicament according to the fifth invention is preferably administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration, or orally.
  • the dosage is determined appropriately based on the condition of the patient, the molecular weight of the active ingredient, and the like.
  • the body weight is preferably 1 kg and the daily dose is preferably about 0.01 mg to 1 mg.
  • the body weight is preferably 1 kg and about 0.1 to 10 mg per day.
  • the fat accumulation inhibitor comprising the peptide according to the fifth invention can be appropriately formulated by a conventional method.For example, 30 mg / l to 300 mg / l of physiological saline can be used. Those dissolved in the concentration range can be used.
  • a so-called drink can be added to a beverage.
  • the peptide according to the sixth invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 19 in the sequence listing. Since the peptide has a function of suppressing allergy (allergy suppressing effect), it is useful as an allergy inhibitor and is applied to medicines, foods, and the like.
  • the peptide according to the sixth aspect of the present invention is blended as an active ingredient and applied to medicines, foods and the like such as allergic inhibitors.
  • allergy inhibitors as medicines can be used for the treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis, etc ..
  • the application of is also included in the category of the allergy suppressant of the present invention.
  • the fat accumulation inhibitor As in the case of the fat accumulation inhibitor, one or more amino acids in the amino acid sequence shown in SEQ ID NO: 19 are substituted or deleted, or one or more amino acids are inserted in the amino acid sequence.
  • a peptide having an added or added amino acid sequence and having an allergy suppressing effect is also included in the scope of the peptide according to the sixth invention of the present invention. It is preferable that the amino acid sequence of such a peptide has 70% or more, more preferably 90% or more homology with the amino acid sequence represented by SEQ ID NO: 19.
  • the allergy inhibitor as a medicament according to the sixth aspect of the present invention is preferably administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration, or orally.
  • the dosage is appropriately determined based on the condition of the patient, the molecular weight of the active ingredient, and the like.
  • the body weight is preferably 1 kg and the daily dose is preferably about 0.1 mg to 0.1 mg.
  • the body weight is preferably about 1 kg, and about 0.1 to 10 mg per day.
  • the allergy inhibitor comprising the peptide according to the sixth invention can be appropriately formulated by a conventional method.For example, a drug dissolved in physiological saline in a concentration range of S OmgZl SOO OmgZl can be used. Can be used. In the case of oral administration, a so-called drink can be added to a beverage.
  • the peptide according to the seventh invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NO: 20, 21 or 22. Since the peptide has a function of lowering blood pressure (blood pressure lowering effect), it is useful as a blood pressure lowering agent, and is applied to medicines, foods and the like.
  • the above-mentioned peptide according to the seventh aspect of the present invention is blended as an active ingredient, and is applied to medicines, foods and the like such as antihypertensive agents.
  • the antihypertensive agent as a medicament can be used for treatment and prevention of hypertension.
  • one or more amino acids in the amino acid sequence shown in SEQ ID NO: 20, 21, or 22 are replaced or deleted, or one or more amino acids are substituted in the amino acid sequence.
  • a peptide having an amino acid sequence in which the amino acid is inserted or added and having a blood pressure lowering effect is also included in the scope of the peptide according to the seventh aspect of the present invention.
  • the amino acid sequence of such a peptide preferably has 70% or more, more preferably 90% or more homology with the amino acid sequence shown in SEQ ID NO: 20, 21 or 22 โ‡ Seventh Invention
  • the antihypertensive agent as a medicament according to the present invention is preferably administered by parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, rectal administration or oral administration.
  • the dosage is determined appropriately based on the condition of the patient, the molecular weight of the active ingredient, and the like.
  • the body weight is preferably about lkg, and about 0.01 mg to 1 mg per day, and for oral administration, about 1 kg, about 0.1 to 10 mg per day is preferable.
  • the antihypertensive comprising the peptide according to the seventh aspect of the present invention can be appropriately formulated by a conventional method.
  • the antihypertensive was dissolved in physiological saline in a concentration range of 30 mg / l to 300 mg / l.
  • a so-called drink can be added to a beverage.
  • the peptide according to the eighth invention of the present invention is a peptide having the amino acid sequence represented by SEQ ID NO: 23 or 24. Since the peptide has a function of relieving pain (analgesic effect), it is useful as an analgesic and is applied to medicines, foods and the like.
  • the peptide according to the eighth aspect of the present invention is blended as an active ingredient and applied to medicines such as analgesics, foods and the like.
  • analgesics as medicines can be used for treatment of headache, menstrual pain and the like.
  • one or more amino acids in the amino acid sequence shown in SEQ ID NO: 23 or 24 are substituted or deleted, or one or more amino acids are added to the amino acid sequence.
  • a peptide having an amino acid sequence into which is inserted or added and having an analgesic effect is also included in the scope of the peptide according to the eighth invention of the present invention.
  • the amino acid sequence of such a peptide preferably has 70% or more, more preferably 90% or more homology with the amino acid sequence represented by SEQ ID NO: 23 or 24.
  • the analgesic as a medicament according to the eighth invention is preferably administered by a parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, rectal administration, or oral administration.
  • the dosage is appropriately determined based on the condition of the patient, the molecular weight of the active ingredient, and the like.
  • the body weight is preferably 1 kg and the daily dose is preferably about 0.0 to 1 mg.
  • the body weight is preferably 1 kg, 0.1 mg per day;
  • the analgesic comprising the peptide according to the eighth invention can be appropriately formulated by a conventional method.
  • a solution dissolved in water at a concentration range of 30 mg / l to 300 Omg / 1 can be used.
  • a so-called drink can be added to a beverage.
  • the peptide according to the ninth invention of the present invention is a peptide having an amino acid sequence represented by SEQ ID NOS: 25, 26, 27, 28, 29, 30, 31 or 32. Since the peptide has a function of promoting central nervous system function (central nervous system function promoting effect), it is useful as a central nervous system function promoter and is applied to medicines, foods, and the like.
  • the above-mentioned peptide according to the ninth aspect of the present invention is blended as an active ingredient, and is applied to pharmaceuticals such as central nervous system function promoters, foods and the like.
  • central nervous system function promoters can be used to prevent cerebral nerve dysfunction due to cerebral ischemic injury or to improve cerebral nerve dysfunction (recovery treatment), etc.
  • the therapeutic agent for improving cerebral nerve dysfunction and application as a drug for central nervous system are also included in the category of the central nervous system function promoter of the present invention.
  • one or more amino acids in the amino acid sequence shown in SEQ ID NO: 25, 26, 27, 28, 29, 30, 31 or 32 are the same.
  • Peptides having an amino acid sequence in which one or more amino acids are substituted or deleted, or one or more amino acids are inserted or added to the amino acid sequence, and which have a central nervous system function promoting effect are also included in the present invention. Included in the range of peptides according to the nine inventions.
  • the amino acid sequence of such a peptide is at least 70%, more preferably 90%, the amino acid sequence represented by SEQ ID NOS: 25, 26, 27, 28, 29, 30, 31 or 32. It is preferable to have the above homology.
  • the agent for promoting central nervous system function as a medicament according to the ninth invention is preferably administered by parenteral route such as intravenous injection, subcutaneous injection, intramuscular injection, or rectal administration, or orally. .
  • the dosage is determined as appropriate based on the condition of the patient, the molecular weight of the active ingredient, and the like.In general, for parenteral administration, the body weight is 1 kg, and the dose is 0.01 mg to 1 mg per day. In the case of oral administration, the body weight is preferably 1 kg and about 0.1 mg to 10 mg per day.
  • the central nervous system function promoter comprising the peptide according to the ninth invention can be appropriately formulated by a conventional method. For example, 30 mg / l to 300 mg Z 1 of physiological saline can be used. Those dissolved in the concentration range can be used. In the case of oral administration, a so-called drink can be added to a beverage.
  • the peptide having the amino acid sequence represented by SEQ ID NOS: 1 to 32 in the sequence listing according to the present invention can be easily synthesized by a well-known peptide chemical synthesis method using a commercially available peptide synthesizer.
  • the synthesis method includes a solid phase method and a liquid phase method.
  • the synthesized peptide is purified according to a usual method. Examples of the purification method include ion exchange chromatography, reverse phase liquid chromatography, affinity chromatography and the like.
  • the peptide of the present invention can also be produced by incorporating a gene corresponding to the amino acid sequence of the peptide of the present invention and an expression promoter into Escherichia coli, yeast and the like by using a gene modification technique.
  • the obtained peptide is analyzed and confirmed with a mass spectrometer or a protein sequencer.
  • the present invention will be described specifically with reference to examples.
  • Example 1 Insulin production promoting action
  • the peptide having the amino acid sequence represented by SEQ ID NO: 1 was synthesized, purified, and confirmed in the following manner by consignment to CSBIO LTD. (Ca1ifornia, U.S.A.). That is, it is synthesized by the solid phase method, the purity is assayed using reversed-phase liquid chromatography (Vy dac C18 column, trifluoroacetic acid Zacetonitrile solvent system), and the molecular weight of the product is analyzed using a mass spectrometer. It was confirmed.
  • HIT cells which are hamster kidney cells that produce insulin (Manufactured by Dainippon Pharmaceutical Co., Ltd.) in RPMI 1640 medium containing 10% fetal bovine serum (source: Dainippon Pharmaceutical Co., Ltd.), and humidified in 5% carbon dioxide gas at 37 nC Nurtured. 1 โ‡ 10 4 wells (we 11) were seeded on a 96-well culture plate by trypsin treatment, and when the culture became confluent, the medium was replaced with a serum-free F12 medium and cultured for 8 hours.
  • the peptide having the amino acid sequence shown in SEQ ID NO: 1 of the present invention synthesized in (1) was dissolved in serum-free RPMI 1640 medium, and added to we11 while changing the dose of HIT cells. The culture was continued for another 12 hours. After the culture, the effect of the peptide on promoting the production of insulin by the cells was measured by insulin immunoassay, and the effect of promoting the production on the non-treated group was determined. In addition, the calculation of the insulin immunoassay and insulin production promotion rates was specifically performed as follows.
  • the cell culture solution supernatant was added to the anti-insulin antibody-fixed well and reacted with the anti-insulin antibody solution while changing the dose.
  • biotin labeled with the antibody was reacted with streptavidin-conjugated peroxidase, and the color development by peroxidase was measured.
  • Insulin concentration was calculated from a standard curve of insulin.
  • the insulin production promotion rate was as follows when the control group without addition of the peptide was set to 100% and the insulin production promotion rate of the group to which the dose was changed was obtained. Table 1 shows the results.
  • the peptide having the amino acid sequence shown in SEQ ID NO: 1 of the present invention acts on hamster-derived insulin-producing cells in a manner that promotes insulin production. Therefore, the peptide having the amino acid sequence shown in SEQ ID NO: 1 of the present invention promotes insulin production, has a function as an insulin production promoter, and is useful as a therapeutic agent for diabetes (insulin production promoter). It can be seen that It can also be seen that it can be used for foods that have an insulin production promoting function.
  • Example 2 Gastric acid secretion inhibitory action
  • the gastric acid secretion inhibitory effect was evaluated by using a rat (Wistar sp.) By combining a peptide having the amino acid sequence represented by SEQ ID NO: 2 of the present invention synthesized in (1) with gastrin that promotes gastric acid secretion in physiological saline. The dissolved solution was injected subcutaneously and evaluated by measuring gastric acid secretion 10 minutes later. Gastrin was administered to the peptide, and the peptide having the amino acid sequence shown in SEQ ID NO: 2 was administered to give 10 g Zkg. Gastric acid secretion was evaluated by fixing the rat to a fixator, inserting a probe into the stomach through the mouth, collecting gastric juice, and measuring the pH. The results are shown in Table 2 below. The control is a result of a control group to which the peptide was not administered.
  • the peptide having the amino acid sequence shown in SEQ ID NO: 2 of the present invention acts on rats to inhibit gastric acid secretion. Therefore, the peptide of the present invention having the amino acid sequence represented by SEQ ID NO: 2 suppresses gastric acid secretion, has a function as a gastric acid secretion inhibitor, and is useful as a therapeutic agent for gastric ulcer and duodenal ulcer (gastric acid secretion inhibitor). You can see that there is. It can also be seen that it can be used for foods that have a gastric acid secretion inhibitory function.
  • Example 3 Growth hormone production promoting action
  • Hamster-derived GH3 cells which are pituitary cells that produce growth hormone (obtained from: IFO (Accession No. 5105)), and F12 medium containing 15% fetal bovine serum (obtained from Dainippon Japan) Pharmaceuticals) and cultivated in a 5% CO2 humidified 37 incubator.
  • IFO Accession No. 5105
  • F12 medium containing 15% fetal bovine serum obtained from Dainippon Japan
  • 1 x 10 4 Z wells were seeded on a 96-well culture plate by trypsin treatment and confluent. The medium was replaced with a 15% serum F12 medium when cultivated for 12 hours, and then the peptide having the amino acid sequence shown in SEQ ID NO: 3 of the present invention synthesized in (1) was replaced with 1%.
  • the dose was changed and added to we11, and the culture was continued for another 3 days.
  • the effect of the peptide on promoting growth hormone production of cells by the growth hormone Imnoassay was examined.
  • the production promoting effect on the untreated group was determined.
  • Growth hormone immunoassay was performed by a standard sandwich ELISA method, in which the cell culture supernatant was added to the anti-growth hormone antibody-fixed well at varying doses and reacted at room temperature for 180 minutes. After washing, a peroxidase-labeled anti-growth hormone antibody was further added, and the mixture was allowed to react at room temperature for 60 minutes. It was measured by degree measurement.
  • Growth hormone concentration was determined based on a standard curve obtained by performing the same sandwich ELISA using a known concentration of growth hormone.
  • the growth hormone production promotion rate was as follows when the control group to which no peptide was added was set to 100%, and the growth hormone production promotion rate of the group to which the dose was changed was calculated. Table 3 shows the results.
  • the peptide having the amino acid sequence shown in SEQ ID NO: 3 of the present invention is a growth hormone-producing cell for growth hormone-producing cells. It was confirmed that it acts to promote production. Therefore, the peptide of the present invention having the amino acid sequence represented by SEQ ID NO: 3 promotes growth hormone production, has a function as a growth hormone production promoter, and is used as a therapeutic agent for dwarf disease (growth hormone production promotion). It is found to be useful as an agent. Also, it can be seen that it can be used for foods that have a growth hormone production promoting function.
  • Example 4 Blood pressure lowering effect
  • SEQ ID NO: 4 5 6, 7, 8, 9, 10, 10, 11 or 12 of the present invention synthesized in (1) was added.
  • a peptide having the amino acid sequence shown was intraperitoneally administered to give 10 jug Z kg, and physiological saline was similarly administered as a control instead of the above peptide solution.
  • the tail artery blood pressure before and 1 hour after administration was measured using a rat tail artery blood pressure / pulse meter (KN-210, manufactured by Natsume Seisakusho). Table 4 shows the results.
  • Adipocytes that accumulate fat were cultured in a 37 ยฐ C. incubator with 5% carbon dioxide gas humidified using an RPM 1 1640 medium containing 10% fetal bovine serum (source: Dainippon Pharmaceutical). 1 โ‡ 10 4 Z holes (we 11) were seeded on a 96-well culture plate, and when confluent, the medium was replaced with a serum-free F 12 medium and cultured for 8 hours. Thereafter, the peptide having the amino acid sequence shown in SEQ ID NOS: 13 and 14 of the present invention synthesized in (1) was dissolved in serum-free RPMI 11640 medium, and added to wel 1 while changing the dose. The culture was continued for another 24 hours.
  • the fat accumulation of the cells by the peptide was determined by the presence or absence of fat granules, The fat accumulation rate for the group was determined.
  • the fat accumulation rate was determined by counting the number of fat accumulated cells in each group by microscopic observation, and expressed as a percentage of the number of fat accumulated cells in the control group to which the peptide was not added. Table 5 shows the results.
  • Rats (Wistar, male, 6 weeks old) were allowed to freely ingest a high-fat diet, and the amino acid sequence represented by SEQ ID NOS: 15, 16, 16, 17 and 18 of the present invention synthesized in the above (1) was obtained every day. 4 weeks after intraperitoneal administration of peptide having Immediately afterwards, blood was collected and the level of triglyceride (TG) in the blood was measured. Each peptide of the present invention was dissolved in physiological saline and injected into the abdominal cavity at a dose of 10 ag / kg. For the control group, physiological saline was similarly injected intraperitoneally. Table 6 shows the results.
  • the peptide of the present invention having the amino acid sequence represented by SEQ ID NOS: 15, 16, 17, and 18 suppresses fat accumulation, is useful as a fat accumulation inhibitor, and It can be seen that it can be used as a medicament for hyperlipidemia as a medicament, an agent for treating fat accumulation, an agent for treating obesity, an agent for preventing obesity, and a food having an inhibitory function on fat accumulation.
  • SEQ ID NOS: 15, 16, 17, and 18 suppresses fat accumulation
  • the peptide of the present invention having an amino acid sequence represented by SEQ ID NO: 19 has a high inhibitory rate of / 3-hexosaminidase release, which is an indicator of histamine release inhibition, and has an allergic inhibitory action ( Function). Therefore, the peptide of the present invention having the amino acid sequence represented by SEQ ID NO: 19 is useful as an allergy inhibitor, and is formulated by mixing the peptide as an active ingredient, as an allergy drug for medicine, a histamine release inhibitor, It can be seen that it can be used for allergy suppressants such as anti-inflammatory agents and foods with allergy suppression function.
  • Example 7 Blood pressure lowering effect
  • a peptide having the amino acid sequence shown in SEQ ID NOS: 20, 21 and 22 of the present invention synthesized in (1) was added to 1 0 zg / kg in the abdominal cavity. Saline was administered. The blood pressure of the tail artery was measured before and 1 hour after administration using a rat tail artery blood pressure / pulse meter (KN-210, manufactured by Natsume Seisakusho). Table 8 shows the results.
  • cerebral ischemia is created by holding the artery for 10 minutes, and the next day, the patient is placed in an eight-way maze to measure the degree of spatial recognition memory. Of the first eight attempts to reach the bait location at each aisle end, the number of correctly reached bait locations is referred to as the โ‡ positive selection number ''. The number of times it reached was defined as the โ€œnumber of errorsโ€ and counted. An increase in the number of positive selections for the control and / or a decrease in the number of errors indicate that the cerebral ischemia has an effect of alleviating the disorder or an early recovery from the disorder. The results are shown in Table 10.
  • SEQ ID NOs: 25, 26, 27, 28, 29, 3 Peptides having the amino acid sequences represented by 0, 31 and 32 are useful as central nervous system function promoters, and are used as prophylactic and therapeutic agents for brain nerve dysfunction as pharmaceuticals by incorporating the peptides as active ingredients. It can be seen that it can be used for central nervous system function promoters such as therapeutic agents for improving cerebral nerve dysfunction, drugs for the central nervous system, cerebral nerve function protectants (drugs), and foods that have the function of promoting central nervous system function.
  • a peptide particularly useful as a medicine or food can be obtained.
  • Peptides having the amino acid sequences represented by SEQ ID NOs: 1 to 32 in the sequence listing of the present invention are particularly useful as insulin production promoters, gastric acid secretion inhibitors, growth hormone production promoters, hypotensive agents, and fat accumulation inhibitors.
  • An allergy inhibitor, an analgesic, a central nervous system function promoter, etc., and a novel amino acid sequence represented by SEQ ID NOS: 1 to 32 in the sequence listing of the present invention, Drugs, foods, etc. can be obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)

Description

ๆ˜Ž ็ดฐ ๆ›ธ ใบใƒ—ใƒใƒ‰ ๆŠ€่ก“ๅˆ†้‡Ž
ๆœฌ็™บๆ˜Žใฏใ€ ใƒšใƒ—ใƒใƒ‰ใซ้–ขใ™ใ‚‹ใ€‚ ใ•ใ‚‰ใซ่ฉณใ—ใใฏใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿ ไฟƒ้€ฒๅŠนๆžœใ€ ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅŠนๆžœใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ€ ่ก€ๅœง้™ ไธ‹ๅŠนๆžœใ€ ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅŠนๆžœใ€ ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅŠนๆžœใ€ ้Žฎ็—›ๅŠนๆžœใ€ ไธญๆžข ็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใซ้–ขใ™ใ‚‹ใ€‚ ่ƒŒๆ™ฏๆŠ€่ก“
ๅพ“ๆฅใ‚ˆใ‚Šใ€ ๅŠน่ƒฝๅŠนๆžœใŒๅ„ชใ‚Œใ€ ๅ‰ฏไฝœ็”จใŒ่ตทใใ‚‹็ญ‰ใฎๆฌ ็‚นใŒใชใ„ๅŒป่–ฌ ๅ“ใฎ้–‹็™บใŒๆฑ‚ใ‚ใ‚‰ใ‚Œใฆใ„ใ‚‹ใ€‚ ไธ€ๆ–นใ€ ็”Ÿไฝ“ๅ†…ใซใฏๆ•ฐๅคšใใฎ็”Ÿ็†ๆดปๆ€ง็‰ฉ ่ณชใŒๅญ˜ๅœจใ—ใ€ ็”Ÿไฝ“ใฎๆญฃๅธธใช็”Ÿๅ‘ฝๆดปๅ‹•ใฎ็ถญๆŒใซๅฏ†ๆŽฅใซ้–ขไธŽใ—ใฆใ„ใ‚‹ใ“ ใจใฏๅ‘จ็Ÿฅใฎไบ‹ๅฎŸใงใ‚ใ‚‹ใ€‚ ใใ‚Œใ‚‰ใฎ็”Ÿไฝ“ๅ†…็”Ÿ็†ๆดปๆ€ง็‰ฉ่ณชๅŠใณๅˆๆˆ็”Ÿ็† ๆดปๆ€ง็‰ฉ่ณชใฏใใ‚Œ่‡ช่บซใ€ ๆ–ฐใ—ใ„ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใจใ—ใฆใฎๅฏ่ƒฝๆ€งใ‚’ๆœ‰ใ™ใ‚‹ ใจๅ…ฑใซใ€ ๆ–ฐใŸใชๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใ‚’้–‹็™บใ™ใ‚‹ใŸใ‚ใฎ็Ÿฅ่ฆ‹ใ‚’ๆไพ›ใ™ใ‚‹ใ‚‚ใฎ ใงใ‚‚ใ‚ใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็›ฎ็š„ใฏใ€ ็‰นใซๅŒป่–ฌใ€ ้ฃŸๅ“ใจใ—ใฆๆœ‰็”จใชใƒšใƒ—ใƒใƒ‰ใ‚’ๆไพ›ใ™ ใ‚‹ใ“ใจใซใ‚ใ‚‹ใ€‚ ็™บๆ˜Žใฎ้–‹็คบ
ๆœฌ้ก˜็™บๆ˜Ž่€…ใฏไธŠ่จ˜่ชฒ้กŒใ‚’่งฃๆฑบใ™ใ‚‹ใŸใ‚ใซ้‹ญๆ„็ ”็ฉถใ‚’่กŒใฃใŸ็ตๆžœใ€ ็‰นๅฎšใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใŒๅ„ชใ‚ŒใŸ็”Ÿ็†ๆดปๆ€งใ‚’ๆœ‰ใ—ใ€ ็‰น ใซๅŒป่–ฌใ€ ้ฃŸๅ“ใจใ—ใฆๆœ‰็”จใงใ‚ใ‚‹ใ“ใจใ‚’่ฆ‹ใ„ใ ใ—ใ€ ๆœฌ็™บๆ˜Žใ‚’ๅฎŒๆˆใ™ใ‚‹ ใซ่‡ณใฃใŸใ€‚
ใ™ใชใ‚ใกใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้… ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎ ใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใ ใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ่ฉฒใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใ€ ๅŠใณๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ ใ‚‹ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚
ใพใŸใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸ ใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ่ฉฒใบใƒ—ใƒ ใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่ƒƒ้…ธๅˆ†ๆณŒ ๆŠ‘ๅˆถๅ‰คใ€ ๅŠใณๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถ ๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚
ใพใŸใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 3ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸ ใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใ€ ๅŠใณๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ ใ™ใ‚‹ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚
ใ•ใ‚‰ใซใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ– ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใ ใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅ ใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่ก€ๅœง้™ไธ‹ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใบใƒ— ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่ก€ๅœง้™ไธ‹ๅ‰คใ€ ๅŠใณๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใ‚’ ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹่ก€ๅœง้™ไธ‹ๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚
ใพใŸใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 3ใ€ 1 4ใ€ 1 5ใ€ 1 6ใ€ 1 7ๅˆใฏ 1 8ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ก ใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—. ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใ ใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่„‚่‚ช่“„็ฉๆŠ‘ ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใ€ ๅŠใณๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ ( ใพใŸใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 9ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ก ใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ่ฉฒใบ ใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ใ‚กใƒฌ ใƒซใ‚ฎไธ€ๆŠ‘ๅˆถๅ‰คใ€ ๅŠใณๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹ใ‚ขใƒฌใƒซ ใ‚ฎไธ€ๆŠ‘ๅˆถๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚
ใพใŸใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅˆใฏ 2 2ใง็คบใ•ใ‚Œใ‚‹ใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅ ใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่ก€ๅœง้™ไธ‹ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ่ฉฒใบ ใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่ก€ๅœง ้™ไธ‹ๅ‰คใ€ ๅŠใณๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹่ก€ๅœง้™ไธ‹ๅ‰คใฎ ใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚
ใพใŸใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—็•ชๅท 2 3ๅˆใฏ 2 4ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ก ใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ็ธ็—›ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ่ฉฒใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ ๅŠนๆˆๅˆ†ใจใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹้Žฎ็—›ๅ‰คใ€ ๅŠใณๅ‰ ่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹้Žฎ็—›ๅ‰คใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ ใงใ‚ใ‚‹ใ€‚ ใ•ใ‚‰ใซใ€ ๆœฌ็™บๆ˜Žใฏใ€ ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅˆใฏ 3 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏ ๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ• ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ไธญ ๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ใ“ใ‚Œใ‚‰ใฎใบใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใ€ ๅŠใณๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ใ™ใ‚‹ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰ค ใฎใ‚ˆใ†ใชๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใงใ‚ใ‚‹ใ€‚ ็™บๆ˜Žใ‚’ๅฎŸๆ–ฝใ™ใ‚‹ใŸใ‚ใฎๆœ€่‰ฏใฎๅฝขๆ…‹
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 1ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใง็คบ ใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ใ‚คใƒณ ใ‚นใƒชใƒณใฎ็”ฃ็”Ÿใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹ใฎใงใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใจ ใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 1ใฎ็™บ ๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ ้€ฒๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจใ—ใฆใฎ ใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฏใ€ ็ณ–ๅฐฟ็—…ใฎๆฒป็™‚ๅŠใณไบˆ้˜ฒใซ็”จใ„ใ‚‹ใ“ใจใŒใง ใใ€ ็ณ–ๅฐฟ็—…ๆฒป็™‚่–ฌใจใ—ใฆใฎๅฟœ็”จใ‚‚ๆœฌ็™บๆ˜Žใฎใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฎ ็ฏ„ใกใ‚†ใ†ใซๅซใพใ‚Œใ‚‹ใ€‚
ใชใŠใ€ ไธ€่ˆฌใซใ€ ็”Ÿ็†ๆดปๆ€งใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใŒใ€ ใใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใฎใ†ใกๅฐ‘ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ใซๅฐ‘ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸๅ ดๅˆใง ใ‚ใฃใฆใ‚‚ใ€ ใใฎ็”Ÿ็†ๆดปๆ€งใ‚’็ถญๆŒใ™ใ‚‹ๅ ดๅˆใŒใ‚ใ‚‹ใ“ใจใฏๅฝ“ๆฅญ่€…ใซๅบƒใ ็Ÿฅใ‚‰ใ‚Œใฆใ„ใ‚‹ใจใ“ใ‚ใงใ‚ใ‚‹ใ€‚ ๅพ“ใฃใฆใ€ ้…ๅˆ—็•ชๅท 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆ ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏ ไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿ ไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 1ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฎ ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ชๅท 1ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 9 0 %ไปฅไธŠ ใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚
ๅ‰่จ˜็ฌฌ 1ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฏใ€ ้™ ่„ˆๆณจๅฐ„ใ€ ็šฎไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ• ไธŽใ™ใ‚‹ใ‹ๅˆใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€… ใฎ็Šถๆ…‹ใ‚„ๆœ‰ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. O l mgใ€œ๏ผš L mg ็จ‹ๅบฆใŒๅฅฝใพใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. 1 mgใ€œ 1 Omg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 1ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบ ใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คใ™ใ‚‹ ใ“ใจใŒใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 3 0mg/ lใ€œ 3 0 0 0mgZ 1 ใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃๆŠ• ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใง ใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 2ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2ใง็คบ ใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ่ƒƒ้…ธ ใฎๅˆ†ๆณŒใ‚’ๆŠ‘ๅˆถใ™ใ‚‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹ใฎใง่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 2ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ ใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“ ็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจใ—ใฆใฎ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใฏใ€ ่ƒƒๆฝฐ็˜ๅŠใณๅไบŒๆŒ‡่…ธๆฝฐ็˜ใฎๆฒป็™‚ๅŠใณไบˆ้˜ฒใซ็”จใ„ใ‚‹ใ“ใจใŒใงใใ€ ่ƒƒ่…ธ ่–ฌใจใ—ใฆใฎๅฟœ็”จใ‚‚ๆœฌ็™บๆ˜Žใฎ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใฎ็ฏ„ใกใ‚†ใ†ใซๅซใพใ‚Œใ‚‹ใ€‚ ใชใŠใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€ ้…ๅˆ—็•ชๅท 2ใซ็คบใ•ใ‚Œ ใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ  ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆ่ƒƒ้…ธๅˆ† ๆณŒๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 2ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ช ๅท 2ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 9 0 %ไปฅ ไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ๅ‰่จ˜็ฌฌ 2ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใฏใ€้™่„ˆๆณจๅฐ„ใ€ ็šฎไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ•ไธŽใ™ใ‚‹ใ‹ ๅˆใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€…ใฎ็Šถๆ…‹ใ‚„ ๆœ‰ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃๆŠ•ไธŽ ใฎๅ ดๅˆใซใฏไฝ“้‡ l k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. 0 1 mgใ€œ l mg็จ‹ๅบฆใŒๅฅฝ ใพใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. l mgใ€œ 1 0 mg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 2ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‹ ใ‚‰ใชใ‚‹่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คใ™ใ‚‹ใ“ใจใŒใงใใ€ ไพ‹ ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 3 0 mgZ l ใ€œ 3 0 0 0 mg/ l ใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใง ๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 3ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 3ใง็คบ ใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ๆˆ้•ท ใƒ›ใƒซใƒขใƒณใฎ็”ฃ็”Ÿใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹ใฎใงๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒ ๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 3 ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆๆˆ้•ทใƒ›ใƒซใƒขใƒณ ็”ฃ็”Ÿไฟƒ้€ฒๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจ ใ—ใฆใฎๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฏใ€ ๅฐไบบ็—‡ใฎๆฒป็™‚ใซ็”จใ„ใ‚‹ใ“ใจใŒใง ใใ‚‹ใ€‚
ใชใŠใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€ ้…ๅˆ—็•ชๅท 3ใซ็คบใ•ใ‚Œ ใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚กใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ  ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆๆˆ้•ทใƒ› ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 3ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ ใƒšใƒ—ใƒใƒ‰ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ใ“ใฎใ‚ˆใ†ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ชๅท 3ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 9 0 %ไปฅไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚
ๅ‰่จ˜็ฌฌ 3ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฏใ€ ้™่„ˆๆณจๅฐ„ใ€ ็šฎไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใง ๆŠ•ไธŽใ™ใ‚‹ใ‹ๅˆใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ ่€…ใฎ็Šถๆ…‹ใ‚„ๆœ‰ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. 0 1 mgใ€œ l m g็จ‹ๅบฆใŒๅฅฝใพใ—ใใ€็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. l mgใ€œ l Omg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 3ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบ ใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คใ™ ใ‚‹ใ“ใจใŒใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 30mgZ lใ€œ 3 0 0 0mg Z 1ใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃ ๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 4ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ่ก€ๅœงใ‚’้™ไธ‹ใ•ใ›ใ‚‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ ใ‚‹ใฎใง่ก€ๅœง้™ไธ‹ๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 4ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ— ใฆ่ก€ๅœง้™ไธ‹ๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌ ใจใ—ใฆใฎ่ก€ๅœง้™ไธ‹ๅ‰คใฏใ€ ้ซ˜่ก€ๅœง็—‡ใฎๆฒป็™‚ๅŠใณไบˆ้˜ฒใซ็”จใ„ใ‚‹ใ“ใจใŒใง ใใ€ ้ซ˜่ก€ๅœง็—‡ๆฒป็™‚่–ฌใจใ—ใฆใฎๅฟœ็”จใ‚‚ๆœฌ็™บๆ˜Žใฎ่ก€ๅœง้™ไธ‹ๅ‰คใฎ็ฏ„ใกใ‚†ใ† ใซๅซใพใ‚Œใ‚‹ใ€‚
ใชใŠใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅ ใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้… ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸ ใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆ่ก€ๅœง้™ไธ‹ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 4ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ† ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพ ใ—ใใฏ 9 0 %ไปฅไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚
ๅ‰่จ˜็ฌฌ 4ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎ่ก€ๅœง้™ไธ‹ๅ‰คใฏใ€ ้™่„ˆๆณจๅฐ„ใ€ ็šฎ ไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ•ไธŽใ™ใ‚‹ใ‹ๅˆ ใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€…ใฎ็Šถๆ…‹ใ‚„ๆœ‰ ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃๆŠ•ไธŽใฎ ๅ ดๅˆใซใฏไฝ“้‡ l k gใ€ 1ๆ—ฅๅฝ“ใŸใ‚Š 0. 0 lmgใ€œ๏ผš Lmg็จ‹ๅบฆใŒๅฅฝใพ ใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1ๆ—ฅๅฝ“ใŸใ‚Š 0. lmgใ€œ l Omg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 4ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ ใชใ‚‹่ก€ๅœง้™ไธ‹ๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คใ™ใ‚‹ใ“ใจใŒใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 30mg/ lใ€œ30 0 OmgZ lใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ— ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซ ๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 5ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 3ใ€ 14ใ€ 1 5ใ€ 1 6ใ€ 1 7ๅˆใฏ 1 8ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ่„‚่‚ชใฎ่“„็ฉใ‚’ๆŠ‘ๅˆถใ™ใ‚‹ๆฉŸ่ƒฝ ๏ผˆ่„‚่‚ช ่“„็ฉๆŠ‘ๅˆถๅŠนๆžœ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใฎใง่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป ่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 5ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒ ใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจใ—ใฆใฎ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฏใ€ ้ซ™่„‚่ก€ ็—‡ใฎๆฒป็™‚ๅŠใณไบˆ้˜ฒ็ญ‰ใซ็”จใ„ใ‚‹ใ“ใจใŒใงใใ€ ้ซ˜่„‚่ก€็—‡็”จๅ‰คใ€ ่‚ฅๆบ€ๆฒป็™‚ ๅ‰คใ€ ่‚ฅๆบ€ไบˆ้˜ฒๅ‰คใจใ—ใฆใฎๅฟœ็”จใ‚‚ๆœฌ็™บๆ˜Žใฎ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฎ็ฏ„ใกใ‚†ใ† ใซๅซใพใ‚Œใ‚‹ใ€‚
ใชใŠใ€ ไธ€่ˆฌใซใ€ ็”Ÿ็†ๆดปๆ€งใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใŒใ€ ใใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใฎใ†ใกๅฐ‘ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ใซๅฐ‘ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸๅ ดๅˆใง ใ‚ใฃใฆใ‚‚ใ€ ใใฎ็”Ÿ็†ๆดปๆ€งใ‚’็ถญๆŒใ™ใ‚‹ๅ ดๅˆใŒใ‚ใ‚‹ใ“ใจใฏๅฝ“ๆฅญ่€…ใซๅบƒใ ็Ÿฅใ‚‰ใ‚Œใฆใ„ใ‚‹ใจใ“ใ‚ใงใ‚ใ‚‹ใ€‚ ๅพ“ใฃใฆใ€ ้…ๅˆ—็•ชๅท 1 3ใ€ 14ใ€ 1 5ใ€ 1 6ใ€ 1 7ๅˆใฏ 1 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎ ใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใ ใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Ž ใฎ็ฌฌ 5ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชในใƒ—ใƒ ใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ชๅท 1 3ใ€ 14ใ€ 1 5ใ€ 1 6ใ€ 1 7ๅˆใฏ 1 8ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 70 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 90 %ไปฅ ไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚
ๅ‰่จ˜็ฌฌ 5ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฏใ€้™่„ˆๆณจๅฐ„ใ€ ็šฎไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ•ไธŽใ™ใ‚‹ใ‹ ๅˆใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€…ใฎ็Šถๆ…‹ใ‚„ ๆœ‰ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃๆŠ•ไธŽ ใฎๅ ดๅˆใซใฏไฝ“้‡ l k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0 . 0 1 m gใ€œl m g็จ‹ๅบฆใŒๅฅฝ ใพใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0 . l m gใ€œ 1 0 m g็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 5ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‹ ใ‚‰ใชใ‚‹่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คๅŒ–ใ™ใ‚‹ใ“ใจใŒใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 3 0 m g / 1ใ€œ 3 0 0 0 m g / 1ใฎๆฟƒๅบฆ็ฏ„ๅ›ฒ ใงๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ใพใŸใ€็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 6ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 9ใง ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ใ‚ก ใƒฌใƒซใ‚ฎไธ€ใ‚’ๆŠ‘ๅˆถใ™ใ‚‹ๆฉŸ่ƒฝ (ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅŠนๆžœ) ใ‚’ๆœ‰ใ™ใ‚‹ใฎใงใ‚กใƒฌ ใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆ ใฐใ€ ๆœฌ็ฌฌ 6ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆใ‚ก ใƒฌใƒซใ‚ฎไธ€ๆŠ‘ๅˆถๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป ่–ฌใจใ—ใฆใฎใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใฏใ€ ใ‚ขใƒˆใƒ”ใƒผๆ€ง็šฎ่†š็‚Žใ€ ๆฐ—็ฎกๆ”ฏๅ–˜ๆฏใ€ ใ‚ขใƒฌใƒซใ‚ฎใƒผๆ€ง้ผป็‚Ž็ญ‰ใฎใ‚ขใƒฌใƒซใ‚ฎใƒผ็–พๆ‚ฃใฎๆฒป็™‚็ญ‰ใซไพ›ใ™ใ‚‹ใ“ใจใŒใงใ. ใ‚ขใƒฌใƒซใ‚ฎใƒผ็”จ่–ฌใ€ ใƒ’ใ‚นใ‚ฟใƒŸใƒณๆ”พๅ‡บๆŠ‘ๅˆถๅ‰คใ€ ๆŠ—็‚Ž็—‡ๅ‰คใจใ—ใฆใฎๅฟœ็”จใ‚‚ ๆœฌ็™บๆ˜Žใฎใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใฎ็ฏ„ใกใ‚†ใ†ใซๅซใพใ‚Œใ‚‹ใ€‚
ใชใŠใ€ ๅ‰่จ˜่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€ ้…ๅˆ—็•ชๅท 1 9ใซ็คบใ•ใ‚Œ ใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ  ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ‚ขใƒฌใƒซ ใ‚ฎใƒผๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 6ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒ ใƒ‰ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ— ็•ชๅท 1 9ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 9 0 %ไปฅไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ๅ‰่จ˜็ฌฌ 6ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใฏใ€ ้™่„ˆๆณจ ๅฐ„ใ€ ็šฎไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ•ไธŽใ™ ใ‚‹ใ‹ๅˆใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€…ใฎ็Šถ ๆ…‹ใ‚„ๆœ‰ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃ ๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1ๆ—ฅๅฝ“ใŸใ‚Š 0. O lmgใ€œ๏ผš Lmg็จ‹ๅบฆ ใŒๅฅฝใพใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1ๆ—ฅๅฝ“ใŸใ‚Š 0. lm gใ€œ 1 Omg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 6ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒ ใƒ‰ใ‹ใ‚‰ใชใ‚‹ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คๅŒ–ใ™ใ‚‹ใ“ใจใŒ ใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ S OmgZ l S O O OmgZ lใฎๆฟƒ ๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ด ๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚ ๆœฌ็™บๆ˜Žใฎ็ฌฌ 7ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—็•ชๅท 20ใ€ 2 1ๅˆใฏ 22ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใบใƒ—ใƒใƒ‰ ใฏใ€ ่ก€ๅœงใ‚’้™ไธ‹ใ•ใ›ใ‚‹ๆฉŸ่ƒฝ ๏ผˆ่ก€ๅœง้™ไธ‹ๅŠนๆžœ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใฎใง่ก€ๅœง้™ไธ‹ ๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 7 ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆ่ก€ๅœง้™ไธ‹ๅ‰ค็ญ‰ ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจใ—ใฆใฎ่ก€ๅœง้™ ไธ‹ๅ‰คใฏใ€ ้ซ˜่ก€ๅœง็—‡ใฎๆฒป็™‚ๅŠใณไบˆ้˜ฒ็ญ‰ใซ็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚
ใชใŠใ€ ๅ‰่จ˜่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€ ้…ๅˆ—็•ชๅท 20ใ€ 2 1ๅˆ ใฏ 22ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎ ๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸ ใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ใงใ‚ใฃใฆ่ก€ๅœง้™ไธ‹ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 7ใฎ็™บๆ˜Žใซไฟ‚ ใ‚‹ในใƒ—ใƒใƒ‰ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชใบใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใฏใ€้…ๅˆ—็•ชๅท 20ใ€ 2 1ๅˆใฏ 22ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 70 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 90 %ไปฅไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ < ๅ‰่จ˜็ฌฌ 7ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎ่ก€ๅœง้™ไธ‹ๅ‰คใฏใ€ ้™่„ˆๆณจๅฐ„ใ€ ็šฎ ไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ•ไธŽใ™ใ‚‹ใ‹ๅˆ ใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€…ใฎ็Šถๆ…‹ใ‚„ๆœ‰ ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃๆŠ•ไธŽใฎ ๅ ดๅˆใซใฏไฝ“้‡ l k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. 0 l mgใ€œ 1 mg็จ‹ๅบฆใŒๅฅฝใพ ใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. l mgใ€œ l Omg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 7ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ ใชใ‚‹่ก€ๅœง้™ไธ‹ๅ‰คใฏใ€ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คๅŒ–ใ™ใ‚‹ใ“ใจใŒใงใใ€ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 3 0mg/ lใ€œ30 0 0mgZ lใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ— ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซ ๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 8ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—็•ชๅท 2 3ๅˆใฏ 24ใง ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ็—› ใฟใ‚’้Žฎใ‚ใ‚‹ๆฉŸ่ƒฝ๏ผˆ้Žฎ็—›ๅŠนๆžœ๏ผ‰ใ‚’ๆœ‰ใ™ใ‚‹ใฎใง้Žฎ็—›ๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 8ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ใบใƒ— ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆ้Žฎ็—›ๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œ ใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจใ—ใฆใฎ้Žฎ็—›ๅ‰คใฏใ€ ้ ญ็—› ยท็”Ÿ็†็—›็ญ‰ใฎๆฒป็™‚ ็ญ‰ใซ็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚
ใชใŠใ€ ๅ‰่จ˜่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€ ้…ๅˆ—็•ชๅท 2 3ๅˆใฏ 24 ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅ ใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ ๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใค ใฆ้Žฎ็—›ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 8ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ ใฎ็ฏ„ๅ›ฒใซๅซใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ช ๅท 2 3ๅˆใฏ 24ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใ ใฏ 9 0 %ไปฅไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚
ๅ‰่จ˜็ฌฌ 8ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎ้Žฎ็—›ๅ‰คใฏใ€ ้™่„ˆๆณจๅฐ„ใ€ ็šฎไธ‹ๆณจ ๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ•ไธŽใ™ใ‚‹ใ‹ๅˆใฏ็ตŒ ๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€…ใฎ็Šถๆ…‹ใ‚„ๆœ‰ๅŠนๆˆ ๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆ ใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0.0 l mgใ€œ l mg็จ‹ๅบฆใŒๅฅฝใพใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. l mgใ€œ๏ผ› L Omg ็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 8ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹้Žฎ ็—›ๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คๅŒ–ใ™ใ‚‹ใ“ใจใŒใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉ ๆฐดใซ 3 0mg/ lใ€œ 3 0 0 Omg/ 1 ใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’ ็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆ ใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใฎ็ฌฌ 9ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅˆใฏ 3 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใ‚‹ใ€‚ ่ฉฒใƒšใƒ—ใƒใƒ‰ใฏใ€ ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆฉŸ ่ƒฝ ๏ผˆไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅŠนๆžœ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใฎใงไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰ค ใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ไพ‹ใˆใฐใ€ ๆœฌ็ฌฌ 9ใฎ ็™บๆ˜Žใซไฟ‚ใ‚‹ๅ‰่จ˜ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝ ไฟƒ้€ฒๅ‰ค็ญ‰ใฎๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใซๅฟœ็”จใ•ใ‚Œใ‚‹ใ€‚ ใ“ใ‚Œใ‚‰ใฎใ†ใกใฎๅŒป่–ฌใจใ—ใฆ ใฎไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใฏใ€ ่„ณ่™š่ก€้šœๅฎณใซใ‚ˆใ‚‹่„ณ็ฅž็ตŒๆฉŸ่ƒฝ้šœๅฎณใฎไบˆ ้˜ฒๅˆใฏ่„ณ็ฅž็ตŒๆฉŸ่ƒฝ้šœๅฎณใฎๆ”นๅ–„ ๏ผˆๅ›žๅพฉๆฒป็™‚๏ผ‰ ็ญ‰ใซ็”จใ„ใ‚‹ใ“ใจใŒใงใใ€ ่„ณ็ฅž็ตŒๆฉŸ่ƒฝ้šœๅฎณไบˆ้˜ฒๆฒป็™‚่–ฌใ€ ่„ณ็ฅž็ตŒๆฉŸ่ƒฝ้šœๅฎณๆ”นๅ–„ๆฒป็™‚่–ฌใ€ ไธญๆžข็ฅž็ตŒ ็ณป็”จ่–ฌใจใ—ใฆใฎๅฟœ็”จใ‚‚ๆœฌ็™บๆ˜Žใฎไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใฎ็ฏ„ใกใ‚†ใ†ใซ ๅซใพใ‚Œใ‚‹ใ€‚
ใชใŠใ€ ๅ‰่จ˜่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใฎๅ ดๅˆใจๅŒๆง˜ใ€ ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅˆใฏ 3 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญ ใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸ ใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚Œ ใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅŠนๆžœ ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚‚ๆœฌ็™บๆ˜Žใฎ็ฌฌ 9ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบใƒ—ใƒใƒ‰ใฎ็ฏ„ๅ›ฒใซๅซ ใพใ‚Œใ‚‹ใ€‚ ใ“ใฎใ‚ˆใ†ใชใƒšใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใฏใ€ ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅˆใฏ 3 2ใง็คบใ™ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใจ 7 0 %ไปฅไธŠใ€ ใ•ใ‚‰ใซๅฅฝใพใ—ใใฏ 9 0 %ไปฅไธŠใฎ็›ธๅŒๆ€งใ‚’ๆœ‰ใ—ใฆใ„ใ‚‹ใ“ ใจใŒๅฅฝใพใ—ใ„ใ€‚
ๅ‰่จ˜็ฌฌ 9ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ๅŒป่–ฌใจใ—ใฆใฎไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใฏใ€ ้™ ่„ˆๆณจๅฐ„ใ€ ็šฎไธ‹ๆณจๅฐ„ใ€ ็ญ‹่‚‰ๅ†…ๆณจๅฐ„ใ€ ็ตŒ็›ด่…ธๆŠ•ไธŽ็ญ‰ใฎ้ž็ตŒๅฃใฎ็ตŒ่ทฏใงๆŠ• ไธŽใ™ใ‚‹ใ‹ๅˆใฏ็ตŒๅฃๆŠ•ไธŽใ™ใ‚‹ใ“ใจใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๆŠ•ไธŽ้‡ใฏใ€ ๆ‚ฃ่€… ใฎ็Šถๆ…‹ใ‚„ๆœ‰ๅŠนๆˆๅˆ†ใฎๅˆ†ๅญ้‡็ญ‰ใซๅŸบใฅใ้ฉๅฎœๆฑบๅฎšใ•ใ‚Œใ‚‹ใŒใ€ ้€šๅธธใ€ ้ž ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. 0 1 mgใ€œ l mg ็จ‹ๅบฆใŒๅฅฝใพใ—ใใ€ ็ตŒๅฃๆŠ•ไธŽใฎๅ ดๅˆใซใฏไฝ“้‡ 1 k gใ€ 1 ๆ—ฅๅฝ“ใŸใ‚Š 0. 1 mgใ€œ 1 0 mg็จ‹ๅบฆใŒๅฅฝใพใ—ใ„ใ€‚ ใพใŸใ€ ๅ‰่จ˜็ฌฌ 9ใฎ็™บๆ˜Žใซไฟ‚ใ‚‹ใบ ใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใฏใ€ ๅธธๆณ•ใซใ‚ˆใ‚Š้ฉๅฎœ่ฃฝๅ‰คๅŒ–ใ™ ใ‚‹ใ“ใจใŒใงใใ€ ไพ‹ใˆใฐใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซ 3 0mg/ lใ€œ 3 0 0 0mg Z 1 ใฎๆฟƒๅบฆ็ฏ„ๅ›ฒใงๆบถ่งฃใ—ใŸใ‚‚ใฎใ‚’็”จใ„ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ใพใŸใ€ ็ตŒๅฃ ๆŠ•ไธŽใฎๅ ดๅˆใซใฏใ€ ้ฃฒๆ–™ใซๆทปๅŠ ใ—ใฆใ„ใ‚ใ‚†ใ‚‹ใƒ‰ใƒชใƒณใ‚ฏๅ‰คใจใ™ใ‚‹ใ“ใจใ‚‚ ใงใใ‚‹ใ€‚
ๆœฌ็™บๆ˜Žใซไฟ‚ใ‚‹้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใ€œ 3 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ๅธ‚่ฒฉใฎใƒšใƒ—ใƒใƒ‰ๅˆๆˆๆฉŸใ‚’็”จใ„ใฆใ€ ๅ‘จ็Ÿฅใฎใบใƒ— ใƒใƒ‰ๅŒ–ๅญฆๅˆๆˆๆณ•ใงๅฎนๆ˜“ใซๅˆๆˆใ™ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚ ๅˆๆˆๆณ•ใจใ—ใฆใฏใ€ ๅ›บ็›ธๆณ•ใพใŸใฏๆถฒ็›ธๆณ•ใŒใ‚ใ‚‹ใ€‚ ๅˆๆˆใ•ใ‚ŒใŸในใƒ—ใƒใƒ‰ใฏ้€šๅธธใฎๆ–นๆณ•ใซๅพ“ ใ„็ฒพ่ฃฝใ•ใ‚Œใ‚‹ใ€‚ ็ฒพ่ฃฝๆ–นๆณ•ใจใ—ใฆใฏใ€ ไพ‹ใˆใฐใ€ ใ‚คใ‚ชใƒณไบคๆ›ใ‚ฏใƒญใƒžใƒˆใ‚ฐ ใƒฉใƒ•ใ‚ฃใƒผใ€ ้€†็›ธๆถฒไฝ“ใ‚ฏใƒญใƒžใƒˆใ‚ฐใƒฉใƒ•ใ‚ฃใƒผใ€ ใ‚กใƒ•ใ‚ฃไบŒใƒ†ใ‚ฃไธ€ใ‚ฏใƒญใƒžใƒˆ ใ‚ฐใƒฉใƒ•ใ‚ฃไธ€็ญ‰ใŒๆŒ™ใ’ใ‚‰ใ‚Œใ‚‹ใ€‚ ใพใŸใ€ ๆœฌ็™บๆ˜Žใฎใƒšใƒ—ใƒใƒ‰ใฏใ€ ้บไผๅญๆ”น ๅค‰ๆŠ€่ก“ใ‚’็”จใ„ใฆใ€ ๆœฌ็™บๆ˜Žใซใ‚ˆใ‚‹ในใƒ—ใƒใƒ‰ใฎใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซๅฏพๅฟœใ™ใ‚‹ ้บไผๅญๅŠใณ็™บ็พใƒ—ใƒญใƒขใƒผใ‚ฟไธ€ใ‚’ๅคง่…ธ่Œใ€ ้…ตๆฏ็ญ‰ใซ็ต„ใฟ่พผใฟใ€ ่ฃฝ้€ ใ™ ใ‚‹ใ“ใจใ‚‚ใงใใ‚‹ใ€‚ ๅพ—ใ‚‰ใ‚ŒใŸใบใƒ—ใƒใƒ‰ใฏ่ณช้‡ๅˆ†ๆžๅ™จใ‚ใ‚‹ใ„ใฏใƒ—ใƒญใƒ†ใ‚ฃ ใƒณใ‚ทใƒผใ‚ฑใƒณใ‚ตไธ€็ญ‰ใงๅˆ†ๆžใ€ ็ขบ่ชใ•ใ‚Œใ‚‹ใ€‚ ไปฅไธ‹ๅฎŸๆ–ฝไพ‹ใ‚’ๆŒ™ใ’ใฆๆœฌ็™บๆ˜Žใ‚’ๅ…ทไฝ“็š„ใซ่ชฌๆ˜Žใ™ใ‚‹ใ€‚
ๅฎŸๆ–ฝไพ‹ 1 ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
้…ๅˆ—็•ชๅท 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ใ€ C S B I O LTD. ( C a 1 i f o r n i a, U. S . A.) ใธใฎๅง”่จ—ใซใ‚ˆ ใ‚Šใ€ ไปฅไธ‹ใฎ่ฆ้ ˜ใงๅˆๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚ ใ™ใชใ‚ใกใ€ ๅ›บ็›ธๆณ• ใซใฆๅˆๆˆใ—ใ€ ้€†็›ธๆถฒไฝ“ใ‚ฏใƒญใƒžใƒˆใ‚ฐใƒฉใƒ•ใ‚ฃไธ€ ๏ผˆVy d a c็คพ่ฃฝ C 1 8 ใ‚ซใƒฉใƒ ใ€ ใƒˆใƒชใƒ•ใƒซใ‚ฉใƒญ้…ข้…ธ Zใ‚กใ‚ปใƒˆใƒ‹ใƒˆใƒชใƒซๆบถๅช’็ณป๏ผ‰ ใ‚’็”จใ„ใฆ็ด”ๅบฆ ใ‚’ๆคœๅฎšใ€ ใพใŸใ€ ่ณช้‡ๅˆ†ๆžๅ™จใซใฆ็”Ÿๆˆ็‰ฉใฎๅˆ†ๅญ้‡ใ‚’็ขบ่ชใ—ใŸใ€‚
(2) ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿ็ดฐ่ƒžใฎใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒ
ใ‚คใƒณใ‚นใƒชใƒณใ‚’็”ฃ็”Ÿใ™ใ‚‹ใƒใƒ ใ‚นใ‚ฟใƒผๅก่‡“็ดฐ่ƒžใงใ‚ใ‚‹ H I T็ดฐ่ƒž ๏ผˆๅ…ฅ ๆ‰‹ๅ…ˆ ๏ผš ๅคงๆ—ฅๆœฌ่ฃฝ่–ฌ๏ผ‰ ใ‚’ 1 0 %็‰›่ƒŽๅ…่ก€ๆธ…ใ‚’ๅซใ‚€ R P M I 1 6 4 0ๅŸน ๅœฐ ๏ผˆๅ…ฅๆ‰‹ๅ…ˆ ๏ผš ๅคงๆ—ฅๆœฌ่ฃฝ่–ฌ๏ผ‰ ใซใฆๅŸน้คŠใ—ใ€ 5 %็‚ญ้…ธใ‚ฌใ‚นๅŠ ๆนฟ 3 7 nCๆ’ ๆธฉๅ™จๅ†…ใซใฆ่‚ฒๆˆใ—ใŸใ€‚ ใƒˆใƒชใƒ—ใ‚ทใƒณๅ‡ฆ็†ใซใ‚ˆใ‚Š 9 6็ฉดๅŸน้คŠใƒ—ใƒฌใƒผใƒˆใซ 1 X 1 0 4ๅ€‹ ็ฉด ๏ผˆw e 1 1 ) ่’”็จฎใ—ใ€ ใ‚ณใƒณใƒ•ใƒซใƒผใ‚งใƒณใƒˆใซใชใฃใŸใจ ใ“ใ‚ใงๅŸนๅœฐใ‚’็„ก่ก€ๆธ… F 1 2ๅŸนๅœฐใซไบคๆ›ใ—ใ€ 8ๆ™‚้–“ๅŸน้คŠใ—ใŸใ€‚ใใฎๅพŒใ€ ( 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’็„ก่ก€ๆธ… R P M I 1 6 4 0ๅŸนๅœฐใซๆบถ่งฃใ—ใ€ H I T็ดฐ่ƒž ใซ็”จ้‡ๅค‰ๅŒ–ใ‚’ใ•ใ›ใชใŒใ‚‰ w e 1 1 ใซๅŠ ใˆใฆใ•ใ‚‰ใซ 1 2ๆ™‚้–“ๅŸน้คŠใ‚’็ถ™ ็ถšใ—ใŸใ€‚ ๅŸน้คŠๅพŒใ€ ๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใซใ‚ˆใ‚‹็ดฐ่ƒžใฎใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠน ๆžœใ‚’ใ‚คใƒณใ‚นใƒชใƒณใฎใ‚ฃใƒ ใƒŽใ‚ขใƒƒใ‚ปใ‚ฃใซใ‚ˆใ‚Šๆธฌๅฎšใ—ใ€ ้žๅ‡ฆ็†็พคใซๅฏพใ™ใ‚‹ ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆฑ‚ใ‚ใŸใ€‚ ใชใŠใ€ ใ‚คใƒณใ‚นใƒชใƒณใฎใ‚ฃใƒ ใƒŽใ‚ขใƒƒใ‚ปใ‚ฃๅŠใณใ‚ฃ ใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็Ž‡ใฎ็ฎ—ๅ‡บใฏๅ…ทไฝ“็š„ใซใฏๆฌกใฎใ‚ˆใ†ใซ่กŒใฃใŸใ€‚ ใ‚ทใƒใƒค ใ‚ฎ ๏ผˆๆ ช๏ผ‰ ใ‚ˆใ‚Šๅธ‚่ฒฉใ•ใ‚Œใฆใ„ใ‚‹ใ‚คใƒณใ‚นใƒชใƒณๆธฌๅฎšใ‚ญใƒƒ ใƒˆใฎๆ‰‹้ †ใซๅพ“ใ„ใ€ ็ดฐ่ƒžๅŸน้คŠๆถฒไธŠๆธ…ใ‚’็”จ้‡ๅค‰ๅŒ–ใ•ใ›ใชใŒใ‚‰ๆŠ—ใ‚ฃใƒณใ‚นใƒชใƒณๆŠ—ไฝ“ใŒๅ›บๅฎšใ•ใ‚Œ ใŸใ‚ฅใ‚จใƒซใซๅŠ ใˆๆŠ—ใ‚คใƒณใ‚นใƒชใƒณๆŠ—ไฝ“ๆบถๆถฒใจๅๅฟœใ•ใ›ใŸใ€‚ ๆคœๅ‡บใฏใ€ ๆŠ—ไฝ“ ใซๆจ™่ญ˜ใ•ใ‚ŒใŸใƒ”ใ‚ชใƒใƒณใ‚’ใ‚นใƒˆใƒฌใƒ—ใƒˆใ‚กใƒ“ใ‚ธใƒณ็ตๅˆใƒšใƒซใ‚ฉใ‚ญใ‚ทใƒ€ใƒผใ‚ผ ใจๅๅฟœใ•ใ›ใ€ ใƒšใƒซใ‚ฉใ‚ญใ‚ทใƒ€ไธ€ใ‚ผใซใ‚ˆใ‚‹็™บ่‰ฒใ‚’ๆธฌๅฎšใ—ใŸใ€‚ ใ‚คใƒณใ‚นใƒชใƒณ ๆฟƒๅบฆใฏใ€ ใ‚คใƒณใ‚นใƒชใƒณใฎๆจ™ๆบ–ๆ›ฒ็ทšใ‹ใ‚‰็ฎ—ๅ‡บใ—ใŸใ€‚ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒ ็Ž‡ใฏๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใ‚’ๅŠ ใˆใชใ„ๅฏพ็…ง็พคใ‚’ 1 0 0 %ใจใ—็”จ้‡ใ‚’ๅค‰ๅŒ–ใ•ใ› ใฆๅŠ ใˆใŸ็พคใฎใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็Ž‡ใ‚’ๆฑ‚ใ‚ใ‚‹ใจๆฌกใฎใ‚ˆใ†ใซใชใฃใŸใ€‚ ็ตๆžœใ‚’่กจ 1ใซ็คบใ™ใ€‚
(่กจ 1 )
ใƒšใƒ—ใƒใƒ‰ๆทปๅŠ ้‡ g/well) ใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็Ž‡ ๏ผˆ๏ผ…)
0
0. 01 1 01 . 9
0. 1
1 1 36. 7
10 141 . 3 ่กจ 1ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ใƒใƒ ใ‚นใ‚ฟใƒผ็”ฑๆฅใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿ็ดฐ่ƒžใซ ๅฏพใ—ใ‚ฃใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็š„ใซไฝœ็”จใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใค ใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ใฏใ‚ฃใƒณใ‚นใƒชใƒณใฎ็”ฃ็”Ÿใ‚’ไฟƒ้€ฒใ—ใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใจใ—ใฆใฎๆฉŸ่ƒฝ ใ‚’ๆœ‰ใ—ใ€ ็ณ–ๅฐฟ็—…ๆฒป็™‚่–ฌ ๏ผˆใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰ค๏ผ‰ ใจใ—ใฆๆœ‰็”จใงใ‚ใ‚‹ ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ใพใŸใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“ใซๆดป็”จ ใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 2 ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1 ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
( 2 ) ใƒฉใƒƒ ๅœใซใŠใ‘ใ‚‹่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถ
่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅŠนๆžœใฏใ€ ใƒฉใƒƒ ใƒˆ ๏ผˆใ‚ฆใ‚ฃใ‚นใ‚ฟใƒผ็จฎ๏ผ‰ ใ‚’็”จใ„ใ€ ๏ผˆ 1 ) ใงๅˆ ๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒ ใƒ‰ใจ่ƒƒ้…ธๅˆ†ๆณŒใ‚’ไฟƒ้€ฒใ™ใ‚‹ใ‚ฌใ‚นใƒˆใƒชใƒณใ‚’็”Ÿ็†้ฃŸๅกฉๆฐดใซๆบถ่งฃใ—ใŸๆบถๆถฒใ‚’ ็šฎไธ‹ๆณจๅฐ„ใ—ใ€ 1 0ๅˆ†ๅพŒใฎ่ƒƒ้…ธๅˆ†ๆณŒใ‚’ๆธฌๅฎšใ™ใ‚‹ใ“ใจใง่ฉ•ไพกใ—ใŸใ€‚ ใ‚ฌใ‚น ใƒˆใƒชใƒณใฏ ใซใชใ‚‹ใ‚ˆใ†ใ€ ้…ๅˆ—็•ชๅท 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏ 1 0 g Z k gใจใชใ‚‹ใ‚ˆใ†ๆŠ•ไธŽใ—ใŸใ€‚ ่ƒƒ้…ธ ๅˆ†ๆณŒใฏใ€ ใƒฉใƒƒ ใƒˆใ‚’ๅ›บๅฎšๅ™จใซๅ›บๅฎšใ—ๅฃใ‚ˆใ‚Šใ‚พใƒณใƒ‡ใ‚’่ƒƒใซๅ…ฅใ‚Œ่ƒƒๆถฒใ‚’ๆŽก ๅ–ใ—ใ€ใใฎ p Hใ‚’ๆธฌๅฎšใ™ใ‚‹ใ“ใจใง่ฉ•ไพกใ—ใŸใ€‚็ตๆžœใ‚’ไธ‹่จ˜่กจ 2ใซ็คบใ™ใ€‚ ใชใŠใ€ ใ‚ณใƒณใƒˆใƒญใƒผใƒซใฏใ€ ๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใ‚’ๆŠ•ไธŽใ—ใชใ‹ใฃใŸๅฏพ็…ง็พคใซใค ใ„ใฆใฎ็ตๆžœใงใ‚ใ‚‹ใ€‚
(่กจ 2 )
ๆŽกๅ–ใ—ใŸ่ƒƒๆถฒใฎ p H
ใ‚ณใƒณใƒˆใƒญใƒผใƒซ 3 . 2
ๆŠ•ไธŽ็พค 4 . 7 ่กจ 2ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ใƒฉใƒƒๅœใซๅฏพใ—่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถ็š„ใซไฝœ็”จใ™ ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2ใซ็คบใ•ใ‚Œใ‚‹ ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏ่ƒƒ้…ธๅˆ†ๆณŒใ‚’ๆŠ‘ๅˆถใ—ใ€ ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถ ๅ‰คใจใ—ใฆใฎๆฉŸ่ƒฝใ‚’ๆœ‰ใ—ใ€ ่ƒƒๆฝฐ็˜ๅŠใณๅไบŒๆŒ‡่…ธๆฝฐ็˜ๆฒป็™‚่–ฌ ๏ผˆ่ƒƒ้…ธๅˆ†ๆณŒ ๆŠ‘ๅˆถๅ‰ค๏ผ‰ ใจใ—ใฆๆœ‰็”จใงใ‚ใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ใพใŸใ€ ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๆฉŸ่ƒฝ ใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“ใซๆดป็”จใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 3 ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1 ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 3ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
( 2 ) ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿ็ดฐ่ƒžใฎๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒ
ๆˆ้•ทใƒ›ใƒซใƒขใƒณใ‚’็”ฃ็”Ÿใ™ใ‚‹่„ณไธ‹ๅž‚ไฝ“็ดฐ่ƒžใงใ‚ใ‚‹ใƒใƒ ใ‚นใ‚ฟใƒผ็”ฑๆฅ G H 3็ดฐ่ƒž ๏ผˆๅ…ฅๆ‰‹ๅ…ˆ๏ผš I F O (ๅ—่จ—็•ชๅท 5 0 1 0 5 ) ใ‚’ 1 5 %็‰›่ƒŽๅ…่ก€ ๆธ…ใ‚’ๅซใ‚€ F 1 2ๅŸนๅœฐ ๏ผˆๅ…ฅๆ‰‹ๅ…ˆ ๏ผšๅคงๆ—ฅๆœฌ่ฃฝ่–ฌ๏ผ‰ ใซใฆๅŸน้คŠใ—ใ€ 5 %็‚ญ้…ธ ใ‚ฌใ‚นๅŠ ๆนฟ 3 7 ๆ’ๆธฉๅ™จๅ†…ใซใฆ่‚ฒๆˆใ—ใŸใ€‚ ใƒˆใƒชใƒ—ใ‚ทใƒณๅ‡ฆ็†ใซใ‚ˆใ‚Š 9 6 ็ฉดๅŸน้คŠใƒ—ใƒฌใƒผใƒˆใซ 1 X 1 0 4ๅ€‹ Z็ฉด ๏ผˆw e l l ) ่’”็จฎใ—ใ€ ใ‚ณใƒณใƒ•ใƒซใƒผ ใ‚งใƒณๅœใซใชใฃใŸใจใ“ใ‚ใงๅŸนๅœฐใ‚’ 1 5 %่ก€ๆธ… F 1 2ๅŸนๅœฐใซไบคๆ›ใ—ใ€ 1 2ๆ™‚้–“ๅŸน้คŠใ—ใŸใ€‚ใใฎๅพŒใ€ ๏ผˆ 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 3ใซ็คบ ใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ 1 5 %่ก€ๆธ… F 1 2ๅŸนๅœฐใซๆบถ ่งฃใ—ใ€ ็”จ้‡ๅค‰ๅŒ–ใ‚’ใ•ใ›ใชใŒใ‚‰ w e 1 1 ใซๅŠ ใˆใฆใ•ใ‚‰ใซ 3ๆ—ฅ้–“ๅŸน้คŠใ‚’ ็ถ™็ถšใ—ใŸใ€‚ ๅŸน้คŠๅพŒใ€ ๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ใซใ‚ˆใ‚‹็ดฐ่ƒžใฎๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ ้€ฒๅŠนๆžœใ‚’ๆˆ้•ทใƒ›ใƒซใƒขใƒณใฎใ‚ฃใƒ ใƒŽใ‚ขใƒƒใ‚ปใ‚ฃใซใ‚ˆใ‚Šๆธฌๅฎšใ—ใ€ ้žๅ‡ฆ็†็พคใซ ๅฏพใ™ใ‚‹็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆฑ‚ใ‚ใŸใ€‚ ใชใŠใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณใฎใ‚ฃใƒ ใƒŽใ‚ขใƒƒใ‚ป ใ‚ฃใฏใ€ๅธธๆณ•ใงใ‚ใ‚‹ใ‚ตใƒณใƒ‰ใ‚คใƒƒใƒ E L I S Aใซใ‚ˆใ‚Š่กŒใฃใŸใ€‚ใ™ใชใ‚ใกใ€ ๆŠ—ๆˆ้•ทใƒ›ใƒซใƒขใƒณๆŠ—ไฝ“ใŒๅ›บๅฎšใ•ใ‚ŒใŸใ‚ฅใ‚จใƒซใซใ€ ็ดฐ่ƒžๅŸน้คŠๆถฒไธŠๆธ…ใ‚’็”จ้‡ ๅค‰ๅŒ–ใ•ใ›ใชใŒใ‚‰ๅŠ ใˆใ€ ๅฎคๆธฉใง 1 8 0ๅˆ†้–“ๅๅฟœใ•ใ›ใ€ ๆด—ๆต„ๅพŒใ€ ใ•ใ‚‰ใซ ใƒšใƒซใ‚ฉใ‚ญใ‚ทใƒ€ใƒผใ‚ผๆจ™่ญ˜ใ—ใŸๆŠ—ๆˆ้•ทใƒ›ใƒซใƒขใƒณๆŠ—ไฝ“ใ‚’ๅŠ ใˆใ€ ๅฎคๆธฉใง 6 0 ๅˆ†้–“ๅๅฟœใ•ใ›ใŸใ€‚ ๆด—ๆต„ๅพŒใ€ ใƒšใƒซใ‚ฉใ‚ญใ‚ทใƒ€ใƒผใ‚ผใซใ‚ˆใ‚‹็™บ่‰ฒๅๅฟœใ‚’ๅธๅ…‰ ๅบฆๆธฌๅฎšใซใ‚ˆใ‚Šๆธฌๅฎšใ—ใŸใ€‚ ๆˆ้•ทใƒ›ใƒซใƒขใƒณๆฟƒๅบฆใฏใ€ ๆ—ข็Ÿฅๆฟƒๅบฆใฎๆˆ้•ทใƒ›ใƒซ ใƒขใƒณใ‚’็”จใ„ใฆๅŒใ˜ใ‚ตใƒณใƒ‰ใ‚คใƒƒใƒ E L I S Aใ‚’่กŒใฃใฆๅพ—ใ‚‰ใ‚ŒใŸๆจ™ๆบ–ๆ›ฒ ็ทšใซๅŸบใฅใๆฑ‚ใ‚ใŸใ€‚ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็Ž‡ใฏใ€ ใƒšใƒ—ใƒใƒ‰ใ‚’ๅŠ ใˆใช ใ„ๅฏพ็…ง็พคใ‚’ 1 0 0 %ใจใ—ใ€ ็”จ้‡ใ‚’ๅค‰ๅŒ–ใ•ใ›ใฆๅŠ ใˆใŸ็พคใฎๆˆ้•ทใƒ›ใƒซใƒข ใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็Ž‡ใ‚’ๆฑ‚ใ‚ใ‚‹ใจๆฌกใฎใ‚ˆใ†ใซใชใฃใŸใ€‚ ็ตๆžœใ‚’่กจ 3ใซ็คบใ™ใ€‚
(่กจ 3 )
Figure imgf000019_0001
่กจ 3ไธญใ€
( * 1 ) ้…ๅˆ—็•ชๅท 3ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ่กจ 3ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 3ใซ็คบใ•ใ‚Œใ‚‹ใ‚กใƒŸใƒŽ ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿ็ดฐ่ƒžใซๅฏพใ—ๆˆ้•ทใƒ›ใƒซ ใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒ็š„ใซไฝœ็”จใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Ž ใฎ้…ๅˆ—็•ชๅท 3ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏๆˆ้•ทใƒ›ใƒซ ใƒขใƒณ็”ฃ็”Ÿใ‚’ไฟƒ้€ฒใ—ใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใจใ—ใฆใฎๆฉŸ่ƒฝใ‚’ๆœ‰ใ—ใ€ ๅฐไบบ็—…็ญ‰ใฎๆฒป็™‚่–ฌ ๏ผˆๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰ค๏ผ‰ ใจใ—ใฆๆœ‰็”จใงใ‚ใ‚‹ใ“ ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ใพใŸใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“ใซๆดป็”จ ใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 4 ่ก€ๅœง้™ไธ‹ไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
( 2) ใƒฉใƒƒ ใƒˆใซใŠใ‘ใ‚‹่ก€ๅœง้™ไธ‹ไฝœ็”จ
1 0้€ฑ้ฝขใฎ่‡ช็„ถ็™บ็—‡้ซ˜่ก€ๅœงใƒขใƒ‡ใƒซใƒฉใƒƒ ใƒˆ ๏ผˆS HRใ€ ้›„๏ผ‰ ใซใ€ ๏ผˆ 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1 ๅˆใฏ 1 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ใ€ 1 0 ju g Z k gใจใชใ‚‹ใ‚ˆใ†ใซ่…น่…”ใซๆŠ•ไธŽใ—ใ€ ใพใŸใ‚ณใƒณใƒˆใƒญใƒผใƒซใจใ—ใฆๅŒๆง˜ใซๅ‰ ่จ˜ในใƒ—ใƒใƒ‰ๆบถๆถฒใฎไปฃใ‚ใ‚Šใซ็”Ÿ็†้ฃŸๅกฉๆฐดใ‚’ๆŠ•ไธŽใ—ใŸใ€‚ ใƒฉใƒƒใƒˆๅฐพๅ‹•่„ˆ่ก€ ๅœง ยท่„ˆๆ‹ๆธฌๅฎš่ฃ…็ฝฎ ๏ผˆKNโ€” 2 1 0ๅž‹ใ€ ๅค็›ฎ่ฃฝไฝœๆ‰€่ฃฝ๏ผ‰ ใ‚’็”จใ„ใฆๆŠ•ไธŽ ๅ‰ๅŠใณ 1ๆ™‚้–“ๅพŒใฎๅฐพๅ‹•่„ˆ่ก€ๅœงใ‚’ๆธฌๅฎšใ—ใŸใ€‚ ็ตๆžœใ‚’่กจ 4ใซ็คบใ™ใ€‚
(่กจ 4)
Figure imgf000020_0001
่กจ 4ไธญใ€
(* 1 ) ้…ๅˆ—็•ชๅท 4ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ (* 2 ) ้…ๅˆ—็•ชๅท 5ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ (* 3) ้…ๅˆ—็•ชๅท 6ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰
( * 4) ้…ๅˆ—็•ชๅท 7ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰
(* 5) ้…ๅˆ—็•ชๅท 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰
( * 6 ) ้…ๅˆ—็•ชๅท 9ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰
(* 7) ้…ๅˆ—็•ชๅท 1 0ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ (* 8) ้…ๅˆ—็•ชๅท 1 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ( * 9 ) ้…ๅˆ—็•ชๅท 1 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ่กจ 4ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ใฏใ€ ่ก€ๅœง้™ไธ‹ไฝœ็”จใ‚’ๆœ‰ใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Ž ใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใซ็คบใ•ใ‚Œ ใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏ่ก€ๅœง้™ไธ‹ๅ‰คใจใ—ใฆใฎๆฉŸ่ƒฝใ‚’ๆœ‰ใ—. ้ซ˜่ก€ๅœง็—‡ใฎๆฒป็™‚่–ฌ ๏ผˆ่ก€ๅœง้™ไธ‹ๅ‰ค๏ผ‰ ใจใ—ใฆๆœ‰็”จใงใ‚ใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ใพใŸใ€ ่ก€ๅœง้™ไธ‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“ใซๆดป็”จใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 5 ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1 ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 1 3ใ€ 1 4ใ€ 1 5ใ€ 1 6ใ€ 1 7 ๅŠใณ 1 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ่ฃฝๅŠ ใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
( 2) ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถไฝœ็”จ ๏ผˆ 1 )
่„‚่‚ช่“„็ฉใ™ใ‚‹่„‚่‚ช็ดฐ่ƒžใ‚’ 1 0 %็‰›่ƒŽๅ…่ก€ๆธ…ใ‚’ๅซใ‚€ R PM 1 1 64 0ๅŸนๅœฐ ๏ผˆๅ…ฅๆ‰‹ๅ…ˆ๏ผš ๅคงๆ—ฅๆœฌ่ฃฝ่–ฌ๏ผ‰ ใ‚’็”จใ„ใฆใ€ 5 %็‚ญ้…ธใ‚ฌใ‚นๅŠ ๆนฟ 3 7 ยฐC ๆ’ๆธฉๅ™จใซใฆๅŸน้คŠใ—ใŸใ€‚ 9 6็ฉดๅŸน้คŠใƒ—ใƒฌใƒผใƒˆใซ 1 X 1 04ๅ€‹ Z็ฉด ๏ผˆw e 1 1 ) ๆ’ญ็จฎใ—ใ€ ใ‚ณใƒณใƒ•ใƒซไธ€ใ‚งใƒณใƒˆใซใชใฃใŸใจใ“ใ‚ใงๅŸนๅœฐใ‚’็„ก่ก€ๆธ… F 1 2ๅŸนๅœฐใซไบคๆ›ใ—ใ€ 8ๆ™‚้–“ๅŸน้คŠใ—ใŸใ€‚ ใใฎๅพŒใ€ ๏ผˆ 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บ ๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 3ๅŠใณ 1 4ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒ ใƒ‰ใ‚’็„ก่ก€ๆธ… R PM 1 1 640ๅŸนๅœฐใซๆบถ่งฃใ—ใ€ ็”จ้‡ๅค‰ๅŒ–ใ•ใ›ใชใŒใ‚‰ w e l 1 ใซๅŠ ใˆใฆใ•ใ‚‰ใซ 2 4ๆ™‚้–“ๅŸน้คŠใ‚’็ถ™็ถšใ—ใŸใ€‚ ๅŸน้คŠๅพŒใ€ ๅ‰่จ˜ใบใƒ— ใƒใƒ‰ใซใ‚ˆใ‚‹็ดฐ่ƒžใฎ่„‚่‚ช่“„็ฉใ‚’่„‚่‚ช้ก†็ฒ’ใฎๆœ‰็„กใซใ‚ˆใ‚Šๅˆคๅฎšใ—ใ€ ้žๅ‡ฆ็† ็พคใซๅฏพใ™ใ‚‹่„‚่‚ช่“„็ฉ็Ž‡ใ‚’ๆฑ‚ใ‚ใŸใ€‚ ใชใŠใ€ ่„‚่‚ช่“„็ฉ็Ž‡ใฏใ€ ้ก•ๅพฎ้ก่ฆณๅฏŸ ใซใ‚ˆใ‚Šใ€ ๅ„็พคใซใŠใ‘ใ‚‹่„‚่‚ช่“„็ฉใ—ใŸ็ดฐ่ƒžๆ•ฐใ‚’่จˆๆ•ฐใ—ใ€ ๅ‰่จ˜ใƒšใƒ—ใƒใƒ‰ ใ‚’ๅŠ ใˆใชใ‹ใฃใŸๅฏพ็…ง็พคใซใŠใ‘ใ‚‹่„‚่‚ช่“„็ฉใ—ใŸ็ดฐ่ƒžๆ•ฐใซๅฏพใ™ใ‚‹็™พๅˆ†็Ž‡ ใง็คบใ—ใŸใ€‚ ็ตๆžœใ‚’่กจ 5ใซ็คบใ™ใ€‚
(่กจ 5 )
Figure imgf000022_0001
่กจ 5ไธญใ€
( * 1 ) ้…ๅˆ—็•ชๅท 1 3ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ( * 2 ) ้…ๅˆ—็•ชๅท 1 4ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ่กจ 5ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 3ๅŠใณ 1 4ใซ็คบใ• ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ็ดฐ่ƒžใฎ่„‚่‚ช่“„็ฉใ‚’้˜ปๅฎณใ—ใ€ ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถไฝœ็”จ๏ผˆๆฉŸ่ƒฝ๏ผ‰ใ‚’ๆœ‰ใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 3ๅŠใณ 1 4ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบ ใƒ—ใƒใƒ‰ใฏใ€ ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ่ฉฒใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆ ๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆๅŒป่–ฌใจใ—ใฆใฎ้ซ˜่„‚่ก€็—‡็”จๅ‰คใ€ ่‚ฅๆบ€ๆฒป็™‚ๅ‰คใ€ ่‚ฅๆบ€ไบˆ ้˜ฒๅ‰ค็ญ‰ใฎ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใ€ ใพใŸ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“็ญ‰ใซ ๆดป็”จใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚
( 3 ) ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถไฝœ็”จ ๏ผˆ2 )
ใƒฉใƒƒใƒˆ ๏ผˆใ‚ฆใ‚ฃใ‚นใ‚ฟใƒผ็จฎใ€้›„ใ€ 6้€ฑ้ฝข๏ผ‰ ใซ้ซ˜่„‚่‚ช้ฃŸใ‚’่‡ช็”ฑๆ‘‚ๅ–ใ•ใ›ใ€ ๆฏŽๆ—ฅๅ‰่จ˜ ๏ผˆ 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 5ใ€ 1 6ใ€ 1 7ๅŠใณ 1 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‚’่…น่…”ๆŠ•ไธŽใ—ใ€ 4้€ฑ ้–“ๅพŒใซ่ก€ๆถฒใ‚’ๆŽกๅ–ใ—ใ€ ่ก€ไธญใฎไธญๆ€ง่„‚่‚ช ๏ผˆTG) ใฎๅ€คใ‚’ๆธฌๅฎšใ—ใŸใ€‚ ๅ‰ ่จ˜ๆœฌ็™บๆ˜Žใฎๅ„ใƒšใƒ—ใƒใƒ‰ใฏ็”Ÿ็†้ฃŸๅกฉๆฐดใซๆบถ่งฃใ—ใ€ ๆŠ•ไธŽ้‡ 1 0 a g/k gใจใชใ‚‹ใ‚ˆใ†่…น่…”ใซๆณจๅฐ„ใ—ใŸใ€‚ ใ‚ณใƒณใƒˆใƒญใƒผใƒซ็พคใซใคใ„ใฆใฏใ€ ็”Ÿ็†้ฃŸ ๅกฉๆฐดใ‚’ๅŒๆง˜ใซ่…น่…”ใซๆณจๅฐ„ใ—ใŸใ€‚ ็ตๆžœใ‚’่กจ 6ใซ็คบใ™ใ€‚
(่กจ 6)
Figure imgf000023_0001
่กจ 6ไธญใ€
(* 1 ) ้…ๅˆ—็•ชๅท 1 5ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ( * 2 ) ้…ๅˆ—็•ชๅท 1 6ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ( * 3 ) ้…ๅˆ—็•ชๅท 1 7ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ( * 4) ้…ๅˆ—็•ชๅท 1 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ่กจ 6ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 5ใ€ 1 6ใ€ 1 7ๅŠ ใณ 1 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้ซ˜่„‚่‚ช้ฃŸ้คŒใƒฉ ใƒƒ ใƒˆใฎ่ก€ไธญไธญๆ€ง่„‚่‚ชๅข—ๅŠ ๆŠ‘ๅˆถไฝœ็”จ ๏ผˆๆฉŸ่ƒฝ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚Œ ใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 5ใ€ 1 6ใ€ 1 7ๅŠใณ 1 8ใซ็คบ ใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ่„‚่‚ชใฎ่“„็ฉใ‚’ๆŠ‘ๅˆถใ—ใ€ ่„‚ ่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆ ใ—ใฆๅŒป่–ฌใจใ—ใฆใฎ้ซ˜่„‚่ก€็—‡็”จๅ‰คใ€ ่‚ฅๆบ€ๆฒป็™‚ๅ‰คใ€ ่‚ฅๆบ€ไบˆ้˜ฒๅ‰ค็ญ‰ใฎ่„‚่‚ช ่“„็ฉๆŠ‘ๅˆถๅ‰คใ€ ใพใŸ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“็ญ‰ใซๆดป็”จใงใใ‚‹ใ“ ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 6 ใ‚กใƒฌใƒซใ‚ฎไธ€ๆŠ‘ๅˆถไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1 ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 1 9ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
(2) ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถไฝœ็”จ
ใƒ’ ใ‚น ใ‚ฟ ใƒŸ ใƒณ้Š้›ขๆŠ‘ๅˆถไฝœ็”จ ใ‚’ ใ€ ๅŒๆ™‚ ใซๆ”พๅ‡บ ใ•ใ‚Œใ‚‹ ๏ผ‰3 โ€” hexosaminidase ๆดปๆ€งใ‚’ๆŒ‡ๆจ™ใจใ—ใฆๆธฌๅฎšใ—ใŸใ€‚ 5 X 1 05ๅ€‹ใฎ R B L - 2 H 3็ดฐ่ƒž ๏ผˆ่ฒกๅ›ฃๆณ•ไบบใƒ’ใƒฅใƒผใƒžใƒณใ‚ตใ‚คใ‚จใƒณใ‚น็ ”็ฉถ่ณ‡ๆบใƒใƒณใ‚ฏใ‚ˆใ‚Š ่ณผๅ…ฅ๏ผ‰ ใ‚’ 4 8 we 1 1ๅŸน้คŠใƒ—ใƒฌใƒผใƒˆใฎๅ„ we 1 1 ใซๆ’ญ็จฎใ—ใ€ 3 % F B Sใ‚’ๅซใ‚€ R PM I 1 6 40ๅŸน้คŠๆถฒใจใจใ‚‚ใซ 3 7 ยฐCใ€ 5 %C02ไธ‹ใง 24ๆ™‚้–“ๅŸน้คŠใ—ใŸใ€‚ ใใฎๅŸน้คŠๆถฒใซไธ‹่จ˜ใฎๅๅฟœๆททๅˆๆถฒ 2 5 0 Lใ‚’ๅŠ  ใˆใ€ 3 7 ยฐCใง 1ๆ™‚้–“ๅๅฟœใ•ใ›ใŸใ€‚ ใใฎๅพŒใ€ ๅ„ we 1 1ใ‹ใ‚‰็ดฐ่ƒžๅค–ๆถฒ 1 0 0 Lใ‚’ๅˆ†ๅ–ใ€ ๆฎ‹ใ‚Šใฎๅค–ๆถฒใ‚’้™คๅŽปใ—ใŸใ€‚ 0. 2 % T r i t o n X- 1 0 0ๆบถๆถฒ 2 5 0 Lใ‚’็”จใ„ใฆๅ„ we l 1ใฎ็ดฐ่ƒžใ‚’ๆบถ่งฃใ—ใฆ็ดฐ ่ƒžๅ†…ๆถฒใจใ—ใ€ I O O Lใ‚’ๅˆ†ๅ–ใ—ใŸใ€‚ ]3โ€”hexosaminidaseๆดปๆ€งใฎๆธฌ ๅฎš ใฏ ๅˆ† ๅ– ใ— ใŸ ใ‚ต ใƒณ ใƒ— ใƒซ ใซ ใ€ 5 m M ใฎ p โ€” ni t rophenyl-2-acetaraido-2-deoxy- ฮฒ -D-gl ucopyr anos i de ( 5 0m Mใ‚ฏใ‚งใƒณ้…ธ็ทฉ่กๆบถๆถฒ๏ผ‰ 40 0 Lใ‚’ๅŠ ใˆใฆๅๅฟœใ•ใ›ใ€ 0. 2 Mใƒ€ใƒช ใ‚ทใƒณ็ทฉ่กๆถฒ ๏ผˆPH 1 0. 7 ) 1 mLๆทปๅŠ ใซใฆๅๅฟœๅœๆญขๅพŒใ€ ็”Ÿๆˆใ—ใŸ p-nitrophenol ใ‚’ 4 0 5 n mใฎๅธๅ…‰ๅบฆใงๆธฌๅฎšใ—ใŸใ€‚ ็ดฐ่ƒžๅค–ใซๆ”พๅ‡บใ• ใ‚Œใ‚‹ ฮฒ -hexosaminidaseๆดปๆ€งใฎๅ‰ฒๅˆใ‚’็ฎ—ๅ‡บใ—ใ€ ใ•ใ‚‰ใซใ‚ตใƒณใƒ—ใƒซใ‚’ๆทป ๅŠ ใ—ใŸๅ ดๅˆใฎใ‚ณใƒณใƒˆใƒญใƒผใƒซใซๅฏพใ™ใ‚‹ๆ”พๅ‡บ้˜ปๅฎณใฎ็จ‹ๅบฆใ‚’่จˆ็ฎ—ใ—ใŸใ€‚
(ๅๅฟœๆททๅˆๆถฒ็ต„ๆˆ๏ผ‰
( 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 9ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ— ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ๏ผˆ 0. 1 mMใ€œ 1 0 mM)ใ€ ใƒ”ใ‚ชใƒใƒณๅŒ–ใƒžใ‚ฆใ‚นๆŠ— D N P I g EๆŠ—ไฝ“ ๏ผˆ 3 g/mL) ใ‚ขใƒ“ใ‚ธใƒณ ๏ผˆ 1 g/mL) ใใ‚Œ ใžใ‚ŒใฎๆฟƒๅŽšๆบถๆถฒใ‚’็”จๆ„ใ—ใ€ releasing medium ( 1 1 6. 9 mM N a C ใ— 5. 4mM KC lใ€ 0. 8 mM Mg S 04ใ€ 5. 6 mM D ไธ€ glucoseใ€ 2 5 mM HEPES, 2. O mM Ca C lใ„ 1 m g /m 1 B S A, p H 7. 7 ) 1 m l ใซๅฏพใ—ใ€ ใใ‚Œใžใ‚Œๆ‹ฌๅผงๅ†…ใฎๆฟƒๅบฆใซใชใ‚‹ ใ‚ˆใ†ๆทปๅŠ ใ™ใ‚‹ใ€‚ ใ‚ตใƒณใƒ—ใƒซใบใƒ—ใƒใƒ‰ใ‚’ๆทปๅŠ ใ—ใชใ„ใ‚‚ใฎใ‚’ใ‚ณใƒณใƒˆใƒญใƒผใƒซ ใจใ™ใ‚‹ใ€‚ ็ตๆžœใ‚’่กจ 7ใซ็คบใ™ใ€‚
(่กจ 7)
Figure imgf000025_0001
่กจ 7ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 9ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸ ใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ใƒ’ใ‚นใ‚ฟใƒŸใƒณๆ”พๅ‡บ้˜ปๅฎณใฎๆŒ‡ๆจ™ใจใชใ‚‹ /3 -hexosaminidaseใฎๆ”พๅ‡บ้˜ปๅฎณ็Ž‡ใŒ้ซ˜ใใ€ใ‚กใƒฌใƒซใ‚ฎไธ€ๆŠ‘ๅˆถไฝœ็”จ๏ผˆๆฉŸ่ƒฝ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 1 9ใซ ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใจใ— ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆๅŒป่–ฌใจใ—ใฆใฎ ใ‚ขใƒฌใƒซใ‚ฎไธ€็”จ่—ฅใ€ ใƒ’ใ‚นใ‚ฟใƒŸใƒณๆ”พๅ‡บๆŠ‘ๅˆถๅ‰คใ€ ๆŠ—็‚Ž็—‡ๅ‰ค็ญ‰ใฎใ‚ขใƒฌใƒซใ‚ฎใƒผ ๆŠ‘ๅˆถๅ‰คใ€ ใพใŸใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“็ญ‰ใซๆดป็”จใงใใ‚‹ใ“ใจ ใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 7 ่ก€ๅœง้™ไธ‹ไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅŠใณ 2 2ใซ็คบใ•ใ‚Œใ‚‹ ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚ (2) ใƒฉใƒƒ ใƒˆใซใŠใ‘ใ‚‹่ก€ๅœง้™ไธ‹ไฝœ็”จ
1 0้€ฑ้ฝขใฎ่‡ช็„ถ็™บ็—‡้ซ˜่ก€ๅœงใƒขใƒ‡ใƒซใƒฉใƒƒ ใƒˆ ๏ผˆS HRใ€ ้›„๏ผ‰ ใซใ€ ๏ผˆ 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅŠใณ 2 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ใ€ 1 0 z g/k gใจใชใ‚‹ใ‚ˆใ†ใซ่…น่…”ใซๆŠ• ไธŽใ—ใ€ ใพใŸใ‚ณใƒณใƒˆใƒญใƒผใƒซใจใ—ใฆๅŒๆง˜ใซๅ‰่จ˜ในใƒ—ใƒใƒ‰ๆบถๆถฒใฎไปฃใ‚ใ‚Šใซ ็”Ÿ็†้ฃŸๅกฉๆฐดใ‚’ๆŠ•ไธŽใ—ใŸใ€‚ ใƒฉใƒƒ ใƒˆๅฐพๅ‹•่„ˆ่ก€ๅœง ยท่„ˆๆ‹ๆธฌๅฎš่ฃ…็ฝฎ ๏ผˆK Nโ€” 2 1 0ๅž‹ใ€ ๅค็›ฎ่ฃฝไฝœๆ‰€่ฃฝ๏ผ‰ ใ‚’็”จใ„ใฆๆŠ•ไธŽๅ‰ๅŠใณ 1ๆ™‚้–“ๅพŒใฎๅฐพๅ‹•่„ˆ่ก€ ๅœงใ‚’ๆธฌๅฎšใ—ใŸใ€‚ ็ตๆžœใ‚’่กจ 8ใซ็คบใ™ใ€‚
(่กจ 8 )
Figure imgf000026_0001
่กจ 8ไธญใ€
( * 1 ) ้…ๅˆ—็•ชๅท 2 0ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ( * 2 ) ้…ๅˆ—็•ชๅท 2 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ( * 3 ) ้…ๅˆ—็•ชๅท 2 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ่กจ 8ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅŠใณ 2 2 ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€่ก€ๅœง้™ไธ‹ไฝœ็”จ ๏ผˆๆฉŸ่ƒฝ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅŠใณ 2 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ่ก€ๅœง้™ ไธ‹ๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆๅŒป่–ฌ ใจใ—ใฆใฎ่ก€ๅœง้™ไธ‹ๅ‰คใ€ ใพใŸ่ก€ๅœง้™ไธ‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“็ญ‰ใซๆดป็”จใงใ ใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 8 ้Žฎ็—›ไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 2 3ๅŠใณ 2 4ใซ็คบใ•ใ‚Œใ‚‹ใ‚ก ใƒŽ ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๅˆๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
( 2 ) ้Žฎ็—›ไฝœ็”จ ใƒฉใƒƒ ใƒˆ ๏ผˆใ‚ฆใ‚ฃใ‚นใ‚ฟใƒผ็จฎ๏ผ‰ ใ‚’ใ€ 1็พคใ‚ใŸใ‚Š 1 0ๅŒน็”จใ„ใฆไปฅไธ‹ใฎๅฎŸ้จ“ ใ‚’่กŒใฃใŸใ€‚ ๏ผˆ 1 )ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 3ๅŠใณ 24ใซ็คบใ•ใ‚Œ ใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ใ€ ็”Ÿ็†้ฃŸๅกฉๆฐดใซๆบถ่งฃใ—ใฆ็šฎไธ‹ๆณจ ๅฐ„ใ—ใ€ 1 0ๅˆ†ๅพŒใฎ็„ก็—›่ฉฆ้จ“ใง่ฉ•ไพกใ—ใŸใ€‚ ๅ‰่จ˜ๆœฌ็™บๆ˜Žใฎใƒšใƒ—ใƒใƒ‰ใฏ 1 O i g Z k gใจใชใ‚‹ใ‚ˆใ†ใซๆŠ•ไธŽใ—ใ€ ใ‚ณใƒณใƒˆใƒญใƒผใƒซใจใ—ใฆ็”Ÿ็†้ฃŸๅกฉๆฐด ใฎใฟใ‚’ๆŠ•ไธŽใ—ใŸใ€‚็„ก็—›่ฉฆ้จ“ใฏใ€ ใƒฉใƒƒใƒˆใ‚’ๅŠ ๆธฉใ—ใŸใƒ›ใƒƒใƒˆใƒ—ใƒฌใƒผใƒˆ๏ผˆ 6 0 ยฐC) ใซใฎใ›ใ€ ้ฃ›ใณไธŠใŒใ‚‹ใพใงใฎๆ™‚้–“ใ‚’ๆธฌๅฎšใ™ใ‚‹ใ“ใจใซใ‚ˆใ‚Šใ€ ๅฎŸๆ–ฝ ใ—ใŸใ€‚ ็ตๆžœใ‚’่กจ 9ใซ็คบใ™ใ€‚
(่กจ 9)
Figure imgf000027_0001
่กจ 9ไธญใ€
(* 1 ) ้…ๅˆ—็•ชๅท 2 3็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ (* 2) ้…ๅˆ—็•ชๅท 24ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ ่กจ 9ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 3ๅŠใณ 24ใซ็คบใ• ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€็—›ใฟใ‚’ๆŠ‘ๅˆถใ—ใ€้Žฎ็—›ไฝœ็”จ๏ผˆๆฉŸ ่ƒฝ๏ผ‰ ใ‚’ๆœ‰ใ™ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 3ๅŠใณ 24ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใฏใ€ ้Žฎ็—›ๅ‰คใจ ใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆ้…ๅˆใ—ใฆๅŒป่–ฌใจใ—ใฆ ใฎ้Žฎ็—›ๅ‰คใ€ใพใŸ้Žฎ็—›ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸๅ“็ญ‰ใซๆดป็”จใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ๅฎŸๆ–ฝไพ‹ 9 ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒไฝœ็”จ
( 1 ) ใบใƒ—ใƒใƒ‰ใฎๅˆๆˆ
ๅฎŸๆ–ฝไพ‹ 1 ใจๅŒๆง˜ใซใ—ใฆใ€ ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0 , 3 1ๅŠใณ 3 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๅˆ ๆˆใ€ ็ฒพ่ฃฝๅŠใณ็ขบ่ชใ‚’่กŒใฃใŸใ€‚
(2) ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒไฝœ็”จ
4้€ฑ้ฝขใฎใ‚ฆใ‚ฃใ‚นใ‚ฟใƒผใƒฉใƒƒใƒˆ ๏ผˆ้›„๏ผ‰ ใ‚’็”จๆ„ใ™ใ‚‹ใ€‚ ๅ…ซๆ–นๆ”พๅฐ„็Šถ่ฟท่ทฏใ‚’ ็”จใ„ใ€ ใ“ใฎ่ฟท่ทฏใฎ็ฉบ้–“่ช่ญ˜ใ‚’ๅฎŒๆˆใ•ใ›ใ‚‹ใƒ™ใ 1้€ฑ้–“ๆฏŽๆ—ฅ่จ“็ทดใ™ใ‚‹ใ€‚ ใ™ใชใ‚ใกใ€ๅŒ่ฟท่ทฏใฎๅ…ซใคใฎ็ซฏใซ้คŒใ‚’็ฝฎใใ€้คŒใ‚’ๅ…จใฆๅ–ใ‚Š็ต‚ใˆใ‚‹ใพใงใ€ ้–“้•ใฃใฆใ™ใงใซ้คŒใ‚’ๅ–ใฃใŸๅ ดๆ‰€ใซไบŒๅบฆไปฅไธŠ้€ฒๅ…ฅใ›ใšใ€ ๅŠน็Ž‡ใ‚ˆใๅ…ซใค ใฎ้คŒใ‚’ๅพ—ใ‚‹ใ‚ˆใ†ใซๅญฆ็ฟ’ใ•ใ›ใ‚‹ใ€‚ ใใฎๅพŒใ€ 3้€ฑ้–“ใ€ ๆŠ•ไธŽ็พคใซใฏ 1 0m g/k gใฎ ๏ผˆ 1 ) ใงๅˆๆˆใ—ใŸๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅŠใณ 3 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ ใƒšใƒ—ใƒใƒ‰ใ‚’่…น่…”ๆณจๅฐ„ใ—ใ€ ๅฏพ็…ง็พคใซใฏ็”Ÿ็†้ฃŸๅกฉๆฐดใ‚’ๆฏŽๆ—ฅๆŠ•ไธŽใ™ใ‚‹ใ€‚ ๆŠ• ไธŽๆœŸ้–“็ต‚ไบ†ๅพŒใ€ 1 0ๅˆ†้–“้กžๅ‹•่„ˆใ‚’ๆŠผใˆใฆ่„ณ่™š่ก€ใฎ็Šถๆ…‹ใ‚’ไฝœใ‚Šใ€ ็ฟŒๆ—ฅ ๅ…ซๆ–น่ฟท่ทฏใซๅ…ฅใ‚Œใฆ็ฉบ้–“่ช่ญ˜่จ˜ๆ†ถใฎ็จ‹ๅบฆใ‚’ๆธฌๅฎšใ™ใ‚‹ใ€‚ ๅ„้€š่ทฏ็ซฏใฎ้คŒใฎ ๅ ดๆ‰€ใซๅˆฐ้”ใ™ใ‚‹ๆœ€ๅˆใฎๅ…ซๅ›žใฎใ†ใกใ€ ้คŒใฎๆฎ‹ใฃใฆใ„ใ‚‹ๅ ดๆ‰€ใซๆญฃใ—ใๅˆฐ ้”ใ—ใŸๅ›žๆ•ฐใ‚’ ใ€Œๆญฃ้ธๆŠžๆ•ฐใ€ใ€ ใพใŸใ€ ้คŒใ‚’ๅ–ใ‚Š็ต‚ใˆใ‚‹ใพใงใซใ€ ้คŒใฎใชใ„ ้€š่ทฏ็ซฏใซๅˆฐ้”ใ—ใŸๅ›žๆ•ฐใ‚’ ใ€Œใ‚จใƒฉไธ€ๆ•ฐใ€ ใจใ—ใ€ ใ‚ซใ‚ฆใƒณใƒˆใ—ใŸใ€‚ ใ‚ณใƒณใƒˆ ใƒญใƒผใƒซใซๅฏพใ™ใ‚‹ๆญฃ้ธๆŠžๆ•ฐใฎๅข—ๅŠ ๅˆใฏใ‚จใƒฉใƒผๆ•ฐใฎๆธ›ๅฐ‘ใ€ ใ‚ใ‚‹ใ„ใฏใใฎ ไธกๆ–นใฏใ€ ่„ณ่™š่ก€ใซใ‚ˆใ‚‹้šœๅฎณใฎ่ปฝๆธ›ใ‚‚ใ—ใใฏใใฎ้šœๅฎณใ‹ใ‚‰ใฎๆ—ฉๆœŸๅ›žๅพฉ ไฝœ็”จใฎใ‚ใ‚‹ใ“ใจใ‚’็คบใ™ใ€‚ ็ตๆžœใ‚’่กจ 1 0ใซ็คบใ™ใ€‚
(่กจ 1 0)
Figure imgf000029_0001
่กจ 1 0ไธญใ€
(* 1 ) ้…ๅˆ—็•ชๅท 2 5ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ (* 2) ้…ๅˆ—็•ชๅท 2 6ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ( * 3 ) ้…ๅˆ—็•ชๅท 2 7ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ (* 4) ้…ๅˆ—็•ชๅท 2 8ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ (* 5) ้…ๅˆ—็•ชๅท 2 9ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ( * 6 ) ้…ๅˆ—็•ชๅท 3 0ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ (* 7) ้…ๅˆ—็•ชๅท 3 1ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ (* 8) ้…ๅˆ—็•ชๅท 3 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ่กจ 1 0ใ‹ใ‚‰ๆ˜Žใ‚‰ใ‹ใชใ‚ˆใ†ใซใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅŠใณ 3 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ ใƒšใƒ—ใƒใƒ‰ใฏใ€ ่„ณ่™š่ก€ใซใ‚ˆใ‚‹้šœๅฎณใ‚’่ปฝๆธ›ใ—ใ€ ใพใŸใใฎ้šœๅฎณใ‹ใ‚‰ๆ—ฉๆœŸใซ ๅ›žๅพฉใ—ใ€ ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆฉŸ่ƒฝใฎใ‚ใ‚‹ใ“ใจใŒ็ขบ่ชใ•ใ‚ŒใŸใ€‚ ใ—ใŸใŒใฃใฆใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅŠใณ 3 2ใซ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ไธญ ๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใจใ—ใฆๆœ‰็”จใงใ‚ใ‚Šใ€ ่ฉฒใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆ้…ๅˆใ—ใฆๅŒป่–ฌใจใ—ใฆใฎ่„ณ็ฅž็ตŒๆฉŸ่ƒฝ้šœๅฎณไบˆ้˜ฒๆฒป็™‚่–ฌใ€ ่„ณ็ฅž็ตŒๆฉŸ่ƒฝ้šœ ๅฎณๆ”นๅ–„ๆฒป็™‚่–ฌใ€ ไธญๆžข็ฅž็ตŒ็ณป็”จ่–ฌใ€ ่„ณ็ฅž็ตŒๆฉŸ่ƒฝไฟ่ญทๅ‰ค ๏ผˆ่–ฌ๏ผ‰ ็ญ‰ใฎไธญๆžข ็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใ€ ใพใŸไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆฉŸ่ƒฝใ‚’ๆœ‰ใ™ใ‚‹้ฃŸ ๅ“็ญ‰ใซๆดป็”จใงใใ‚‹ใ“ใจใŒๅˆ†ใ‹ใ‚‹ใ€‚ ็”ฃๆฅญไธŠใฎๅˆฉ็”จๅฏ่ƒฝๆ€ง
ไปฅไธŠใ€ ่ฉณ่ฟฐใ—ใŸใ‚ˆใ†ใซๆœฌ็™บๆ˜Žใซใ‚ˆใ‚Œใฐใ€ ็‰นใซๅŒป่–ฌใ€ ้ฃŸๅ“ใจใ—ใฆๆœ‰ ็”จใชใƒšใƒ—ใƒใƒ‰ใŒๅพ—ใ‚‰ใ‚Œใ‚‹ใ€‚ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใ€œ 3 2ใง็คบ ใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใฏใ€ ็‰นใซใ€ ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ ้€ฒๅ‰คใ€ ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใ€ ่ก€ๅœง้™ไธ‹ๅ‰คใ€ ่„‚ ่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใ€ ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใ€ ้Žฎ็—›ๅ‰คใ€ ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰ค ็ญ‰ใฎๆฉŸ่ƒฝใ‚’ๆœ‰ใ—ใ€ ๆœฌ็™บๆ˜Žใฎ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใ€œ 3 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ก ใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ‚’็”จใ„ใ‚Œใฐใ€ ๆ–ฐ่ฆใชๅŒป่–ฌใ€ ้ฃŸๅ“็ญ‰ใ‚’ๅพ— ใ‚‹ใ“ใจใŒใงใใ‚‹ใ€‚

Claims

่ซ‹ ๆฑ‚ ใฎ ็ฏ„ ๅ›ฒ
I .้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ— ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆท ๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆ. ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€‚
2 . ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ€‚
3 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1ๅˆใฏ 2้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ ็”Ÿไฟƒ้€ฒๅ‰คใ€‚
4 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1ๅˆใฏ 2้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
5 . ใ‚คใƒณใ‚นใƒชใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 4้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ ้ฃŸๅ“ใ€‚
6 .้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ— ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟ ๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆ. ่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€‚
7 . ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 6้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ€‚
8 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 6ๅˆใฏ 7้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถ ๅ‰คใ€‚
9 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 6ๅˆใฏ 7้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ—ใฆๅซๆœ‰ ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
1 0 .่ƒƒ้…ธๅˆ†ๆณŒๆŠ‘ๅˆถๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 9้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
I I . ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 3ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒ ใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ— ่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธ ใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ ใคใฆใ€ ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€‚
1 2. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 3ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒ ใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 1้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ€‚
1 3. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 1ๅˆใฏ 1 2้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ๆˆ้•ทใƒ› ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใ€‚
1 4. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 1ๅˆใฏ 1 2้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
1 5. ๆˆ้•ทใƒ›ใƒซใƒขใƒณ็”ฃ็”Ÿไฟƒ้€ฒๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 4้ …่จ˜่ผ‰ใฎๅŒป ่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
1 6. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ 1 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่ก€ๅœง้™ไธ‹ๅŠนๆžœใ‚’ ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€‚
1 7. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 4ใ€ 5ใ€ 6ใ€ 7ใ€ 8ใ€ 9ใ€ 1 0ใ€ 1 1ๅˆใฏ
1 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 6้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ€‚
1 8. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 6ๅˆใฏ 1 7้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่ก€ๅœง้™ ไธ‹ๅ‰คใ€‚
1 9. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 6ๅˆใฏ 1 7้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
2 0. ่ก€ๅœง้™ไธ‹ๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 1 9้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
2 1. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 3ใ€ 1 4ใ€ 1 5ใ€ 1 6ใ€ 1 7ๅˆใฏ 1 8ใง ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญ ใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸ ใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚Œ ใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€‚
2 2 . ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 3ใ€ 1 4ใ€ 1 5ใ€ 1 6ใ€ 1 7ๅˆใฏ 1 8ใง ็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ ๅ›ฒ็ฌฌ 2 1้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ€‚
2 3 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 1ๅˆใฏ 2 2้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่„‚่‚ช่“„ ็ฉๆŠ‘ๅˆถๅ‰คใ€‚
2 4 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 1ๅˆใฏ 2 2้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
2 5 . ่„‚่‚ช่“„็ฉๆŠ‘ๅˆถๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 4้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ้ฃŸ ๅ“ใ€‚
2 6 . ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 9ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ— ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ› ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚กใƒŸใƒŽ ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใง ใ‚ใฃใฆใ€ ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€‚
2 7 . ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 1 9ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ— ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 6้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ€‚
2 8 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 6ๅˆใฏ 2 7้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ใ‚ขใƒฌใƒซ ใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใ€‚
2 9 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 6ๅˆใฏ 2 7้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
3 0 . ใ‚ขใƒฌใƒซใ‚ฎใƒผๆŠ‘ๅˆถๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 2 9้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ ้ฃŸๅ“ใ€‚
3 1 . ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅˆใฏ 2 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ ใ‚‹ในใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธ ใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎ ใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ— ใƒใƒ‰ใงใ‚ใฃใฆใ€ ่ก€ๅœง้™ไธ‹ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€‚
3 2 . ้…ๅˆ—็•ชๅท 2 0ใ€ 2 1ๅˆใฏ 2 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ ใ‚‹ในใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 1้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ€‚
3 3 . ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 1ๅˆใฏ 3 2้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹่ก€ๅœง้™ ไธ‹ๅ‰คใ€‚
3 4. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 1ๅˆใฏ 3 2้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
3 5. ่ก€ๅœง้™ไธ‹ๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 4้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
3 6. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2 3ๅˆใฏ 2 4ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—ใ€ ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐ ใฎใ‚ขใƒŸใƒŽ้…ธใŒๆŒฟๅ…ฅใ•ใ‚Œ่‹ฅใ—ใใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบ ใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ้Žฎ็—›ๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใ€‚
3 7. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2 3ๅˆใฏ 2 4ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 6้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰,
3 8.่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 6ๅˆใฏ 3 7้ …่จ˜่ผ‰ใฎใบใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹้Žฎ็—›ๅ‰คใ€‚
3 9. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 6ๅˆใฏ 3 7้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
4 0. ้Žฎ็—›ๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 3 9้ …่จ˜่ผ‰ใฎๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
4 1. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅˆใฏ 3 2ใง็คบใ•ใ‚Œใ‚‹ใ‚กใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€ ๆˆ–ใ„ใฏ่ฉฒใ‚ก ใƒŸใƒŽ้…ธ้…ๅˆ—ไธญใฎ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒ็ฝฎๆ›ใ—่‹ฅใ—ใใฏๆฌ ๅคฑใ—- ๅˆใฏ่ฉฒใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใซ 1่‹ฅใ—ใใฏ่ค‡ๆ•ฐใฎใ‚ขใƒŸใƒŽ้…ธใŒๆทๅ…ฅใ•ใ‚Œ่‹ฅใ—ใ ใฏไป˜ๅŠ ใ•ใ‚ŒใŸใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใƒšใƒ—ใƒใƒ‰ใงใ‚ใฃใฆใ€ ไธญๆžข็ฅž็ตŒ็ณป ๆฉŸ่ƒฝไฟƒ้€ฒๅŠนๆžœใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ€‚
42. ้…ๅˆ—่กจใฎ้…ๅˆ—็•ชๅท 2 5ใ€ 2 6ใ€ 2 7ใ€ 2 8ใ€ 2 9ใ€ 3 0ใ€ 3 1ๅˆใฏ 3 2ใง็คบใ•ใ‚Œใ‚‹ใ‚ขใƒŸใƒŽ้…ธ้…ๅˆ—ใ‚’ๆœ‰ใ™ใ‚‹ใบใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจ ใ™ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 4 1้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ€‚
43. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 4 1ๅˆใฏ 42้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‹ใ‚‰ใชใ‚‹ไธญๆžข็ฅž ็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใ€‚
44. ่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 4 1ๅˆใฏ 42้ …่จ˜่ผ‰ใฎใƒšใƒ—ใƒใƒ‰ใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ— ใฆๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌๅˆใฏ้ฃŸๅ“ใ€‚
4 5. ไธญๆžข็ฅž็ตŒ็ณปๆฉŸ่ƒฝไฟƒ้€ฒๅ‰คใงใ‚ใ‚‹่ซ‹ๆฑ‚ใฎ็ฏ„ๅ›ฒ็ฌฌ 44้ …่จ˜่ผ‰ใฎๅŒป่–ฌ ๅˆใฏ้ฃŸๅ“ใ€‚
PCT/JP2003/001333 2002-02-08 2003-02-07 Peptides WO2003066672A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003211501A AU2003211501A1 (en) 2002-02-08 2003-02-07 Peptides
JP2003566043A JPWO2003066672A1 (ja) 2002-02-08 2003-02-07 ใƒšใƒ—ใƒใƒ‰

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002032419 2002-02-08
JP2002-32419 2002-02-08
JP2002-205063 2002-07-15
JP2002205063 2002-07-15

Publications (1)

Publication Number Publication Date
WO2003066672A1 true WO2003066672A1 (fr) 2003-08-14

Family

ID=27736464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/001333 WO2003066672A1 (fr) 2002-02-08 2003-02-07 Peptides

Country Status (3)

Country Link
JP (1) JPWO2003066672A1 (ja)
AU (1) AU2003211501A1 (ja)
WO (1) WO2003066672A1 (ja)

Citations (10)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
WO1994009828A1 (en) * 1992-11-03 1994-05-11 Synaptic Pharmaceutical Corporation Dna encoding a human serotonin receptor (5-ht4b) and uses thereof
WO1995019568A1 (en) * 1994-01-14 1995-07-20 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use
WO1998014479A1 (fr) * 1996-10-02 1998-04-09 Kenji Sakamoto Procede de recherche de substances physiologiquement actives et procede de production de telles substances
WO1999051627A1 (fr) * 1998-04-04 1999-10-14 Nakoshi, Hideo Methode de recherche de substances physiologiquement actives, procede de production de ces substances et medicaments decouverts par la methode de recherche
US6030804A (en) * 1995-06-06 2000-02-29 Human Genome Sciences, Inc. Polynucleotides encoding G-protein parathyroid hormone receptor HLTDG74 polypeptides
JP2001098000A (ja) * 1999-09-29 2001-04-10 Kenji Sakamoto ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใฎๅŒป่–ฌ็”จ้€”
WO2001040265A2 (en) * 1999-12-02 2001-06-07 V.I. Technologies, Inc. Ligands for a target molecule and a method for indentifying them
WO2001077172A2 (en) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
JP2001335596A (ja) * 2000-05-24 2001-12-04 Kenji Sakamoto ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใฎๅŒป่–ฌ็”จ้€”

Patent Citations (10)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
WO1994009828A1 (en) * 1992-11-03 1994-05-11 Synaptic Pharmaceutical Corporation Dna encoding a human serotonin receptor (5-ht4b) and uses thereof
WO1995019568A1 (en) * 1994-01-14 1995-07-20 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use
US6030804A (en) * 1995-06-06 2000-02-29 Human Genome Sciences, Inc. Polynucleotides encoding G-protein parathyroid hormone receptor HLTDG74 polypeptides
WO1998014479A1 (fr) * 1996-10-02 1998-04-09 Kenji Sakamoto Procede de recherche de substances physiologiquement actives et procede de production de telles substances
WO1999051627A1 (fr) * 1998-04-04 1999-10-14 Nakoshi, Hideo Methode de recherche de substances physiologiquement actives, procede de production de ces substances et medicaments decouverts par la methode de recherche
JP2001098000A (ja) * 1999-09-29 2001-04-10 Kenji Sakamoto ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใฎๅŒป่–ฌ็”จ้€”
WO2001040265A2 (en) * 1999-12-02 2001-06-07 V.I. Technologies, Inc. Ligands for a target molecule and a method for indentifying them
WO2001077172A2 (en) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
JP2001335596A (ja) * 2000-05-24 2001-12-04 Kenji Sakamoto ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใฎๅŒป่–ฌ็”จ้€”

Non-Patent Citations (4)

* Cited by examiner, โ€  Cited by third party
Title
CHIJEN LIN ET AL.: "Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth", NATURE, vol. 360, 1992, pages 765 - 768, XP002962150 *
KLEMENS KAUPMANN ET AL.: "Expression cloning of GABAb receptors uncovers similarity metabotropic glutamate receptor", NATURE, vol. 386, 1997, pages 239 - 246, XP002924147 *
LEE PAUL H.K. ET AL.: "Cloning and expression of a cDNA encoding bovine muscarinic acetylcholine m3 receptor", BIOCHEM. BIOPHYS. ACTA, vol. 1223, 1994, pages 151 - 154, XP002916491 *
LOMASNEY JON W. ET AL.: "Expansion of the alpha2-adrenergic receptor family: cloning and characterization of a human alpha2-adrenergic receptor subtype, the gene for which is located on chromo some 2", PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 5094 - 5098, XP002158508 *

Also Published As

Publication number Publication date
JPWO2003066672A1 (ja) 2005-06-09
AU2003211501A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
JP7654587B2 (ja) ใƒšใƒ—ใƒใƒ‰็ต„ๆˆ็‰ฉ
AU2022279420B2 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
US5418218A (en) Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
JP3987645B2 (ja) ใƒ‹ใ‚ณใƒใƒณใ‚ขใƒŸใƒ‰่ช˜ๅฐŽไฝ“ๅŠใณๅŒป่–ฌใจใ—ใฆใฎใใ‚Œใ‚‰ใฎไฝฟ็”จ
JP4562394B2 (ja) ้žใ‚ขใ‚ทใƒซๅŒ–ใ‚ฐใƒฌใƒชใƒณใ‚’ๅซใ‚€ๅŒป่–ฌ็ต„ๆˆ็‰ฉใŠใ‚ˆใณใใฎๆฒป็™‚็š„ไฝฟ็”จ
CN104395338B (zh) ไบบ่ƒฐๅฒ›ๆท€็ฒ‰ๆ ทๅคš่‚ฝ็ฑปไผผ็‰ฉ
EA020497B1 (ru) ะะฝะฐะปะพะณะธ ะณะปัŽะบะฐะณะพะฝะฐ
EA020520B1 (ru) ะะฝะฐะปะพะณะธ ะณะปัŽะบะฐะณะพะฝะฐ
CN103732618A (zh) ๆ–ฐๅž‹ๆณŒ้…ธ่ฐƒ่Š‚่‚ฝ่ก็”Ÿ็‰ฉๅ’ŒๅŒ…ๅซ่ฏฅๆณŒ้…ธ่ฐƒ่Š‚่‚ฝ่ก็”Ÿ็‰ฉ็š„็”จไบŽๆฒป็–—่‚ฅ่ƒ–็š„่ฏ็‰ฉ็ป„ๅˆ็‰ฉ
WO2006126673A1 (ja) ็ต„ใฟๅˆใ‚ใ›ใซใ‚ˆใ‚‹็ณ–ๅฐฟ็—…ๆฒป็™‚่–ฌ
WO2001060370A1 (fr) Remedes contre les maladies induites par l&#39;endotheline
US7081473B2 (en) Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient
CN103987408A (zh) ้€š่ฟ‡่ฏ็†ๅญฆ้ถๅ‘Kv1.3้’พ้€š้“ๆฒป็–—่‚ฅ่ƒ–ๅ’Œ่‚ฅ่ƒ–็›ธๅ…ณ็—…็—‡
KR102624902B1 (ko) ๋…ธ๋‚˜ํŽฉํƒ€์ด๋“œ์˜ ์‹ ๊ทœ ์šฉ๋„
WO2024078507A1 (zh) ้บฆ่ง’็”พ้†‡ๅœจๅˆถๅค‡้˜ฒๆฒป่ƒƒๆบƒ็–ก่ฏ็‰ฉไธญ็š„ๅบ”็”จ
WO2003066672A1 (fr) Peptides
TW201032810A (en) Treatment for glomerulonephritis
JP3398255B2 (ja) ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใ‚Œใ‚’ๆœ‰ๅŠนๆˆๅˆ†ใจใ™ใ‚‹้ชจ็–พๆ‚ฃๆฒป็™‚่–ฌ
CN115212204B (zh) ไธ€็งๅŒ–ๅˆ็‰ฉๅœจๅˆถๅค‡ๆฒป็–—้˜ฟๅฐ”่Œจๆตท้ป˜็—‡่ฏ็‰ฉไธญ็š„็”จ้€”
JP2001335596A (ja) ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใฎๅŒป่–ฌ็”จ้€”
CN101108178A (zh) ไธ€็งไบฒ็Žฏ็ด aๆŠ‘ๅˆถๅ‰‚ๅœจๅˆถๅค‡ๆŠ—่‰พๆป‹็—…่ฏ็‰ฉไธญ็š„ๅบ”็”จ
JPH03284694A (ja) ๆ–ฐ่ฆใƒˆใƒชใƒšใƒ—ใƒใƒ‰ๅŠใณ่ก€ๅœง้™ไธ‹ๅ‰ค
WO2023185156A1 (zh) ไธ€็ฑปๅคš่‚ฝๅŒ–ๅˆ็‰ฉๅŠๅ…ถๅˆถๅค‡ๆ–นๆณ•ๅ’Œๅบ”็”จ
JP2001098000A (ja) ๆ–ฐ่ฆใƒšใƒ—ใƒใƒ‰ๅŠใณใใฎๅŒป่–ฌ็”จ้€”
KR20210084592A (ko) Rho ํ‚ค๋‚˜์•„์ œ ์–ต์ œ์ œ, ์ด๋ฅผ ์ œ์กฐํ•˜๊ธฐ ์œ„ํ•œ ๋ฐฉ๋ฒ• ๋ฐ ์ด์˜ ์šฉ๋„

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003566043

Country of ref document: JP

122 Ep: pct application non-entry in european phase